INTRODUCTION {#S1}
============

The appearance of sunlight and the advent of oxygen on Earth were undoubtedly the most dramatic environmental changes during evolution ([@R75]). As a result, almost all organisms on this planet are equipped with light- and oxygen-sensing pathways. Light- and oxygen-sensing pathways are linked on a cellular level in mammals ([@R25]; [@R29]; [@R42]). Hypoxia-inducible factor 1α (HIF1A), an evolutionarily conserved transcription factor enabling cellular adaptation to low oxygen availability ([@R58]), belongs to the same protein family as the light-inducible circadian core protein Period 2 (PER2) ([@R38]). Both belong to the *PAS* domain superfamily of signal sensors for oxygen, light, or metabolism ([@R29]; [@R64]). As such, *Hif1α* mRNA levels cycle in a circadian manner in mouse cardiac tissue ([@R15]), and rhythmic oxygen levels reset the circadian clock through HIF1A ([@R1]). This evolutionarily conserved relationship between light (circadian)- and oxygen-sensing pathways suggests a role for light-elicited circadian rhythm proteins in disease states of low oxygen availability, such as myocardial ischemia.

In our studies, we sought to develop a cardioprotective strategy using light to target and manipulate PER2 function and uncover mechanisms of PER2-dependent adaptation to hypoxia or ischemia ([@R15]). In a comprehensive and systems biology approach, we dissected light- and hypoxia-elicited pathways in mice and humans from a cellular level to the whole body. Our investigations revealed that circadian PER2 functions at the crossroads between light-elicited circadian amplitude enhancement and transcriptional HIF1A-dependent adaptation to oxygen depletion in hypoxia or ischemia. We demonstrate a mechanistic understanding of cardioprotection with light therapy by targeting and manipulating hypoxic pathways to reduce infarct sizes after myocardial ischemia.

RESULTS {#S2}
=======

Intense Light-Elicited Cardiac PER2 Amplitude Enhancement as a Cardioprotective Mechanism {#S3}
-----------------------------------------------------------------------------------------

Intense light is the dominant regulator of human circadian rhythms and PER2 activity ([@R2]; [@R51]). Here we investigated intense light exposure protocols and found that housing mice under intense light conditions (10,000 lux, full spectrum, UV filter, L \[light\]:D \[dark\] phase 14:10 h) robustly enhances cardioprotection, reflected as a time-dependent decrease in infarct size and circulating troponin-I levels ([Figures 1A](#F1){ref-type="fig"}--[1C](#F1){ref-type="fig"}). Evaluation of locomotor activity during intense light conditions, as determined by wheel running, excluded a phase shift of the circadian period but identified increases of the total distance walked or the circadian amplitude ([Figures 1D](#F1){ref-type="fig"}--[1F](#F1){ref-type="fig"}; [Figure S1](#SD1){ref-type="supplementary-material"}). Housing PER2 reporter mice under intense light for one week revealed increases in the circadian peak and trough levels of cardiac PER2 protein levels ([Figure 1G](#F1){ref-type="fig"}). Further analysis of wheel running activity in *Per2*^−/−^ mice demonstrated intense light-elicited increases of the total distance walked or the circadian amplitude to be PER2 dependent ([Figures 1H](#F1){ref-type="fig"}--[1J](#F1){ref-type="fig"}; [Figure S1](#SD1){ref-type="supplementary-material"}).

To confirm that cardiac circadian PER2 amplitude enhancement requires visual light perception, we enucleated wild-type mice to remove light-sensing structures. Ocular enucleation induced a complete loss of PER2 stabilization in blind mice exposed to intense light conditions compared with seeing animals ([Figures 1K](#F1){ref-type="fig"} and [1L](#F1){ref-type="fig"}). Myocardial ischemia and reperfusion studies of blind mice under room light housing conditions found shifted cardiac troponin kinetics (troponin blind, Zeitgeber 3 \[ZT3; 9 a.m.\] \< ZT15 \[9 p.m.\], versus troponin seeing, ZT3 \> ZT15) and slightly overall higher troponin levels in blind mice (troponin blind versus troponin seeing: 168 versus 118 ng/mL, not significant), indicating a lack of circadian synchronization by light ([Figure 1M](#F1){ref-type="fig"}; [Figure S1](#SD1){ref-type="supplementary-material"}). Wheel running activity in blind mice demonstrated the abolished increase of the circadian amplitude similar to that seen with *Per2*^−/−^ mice ([Figure 1N](#F1){ref-type="fig"}; [Figure S1](#SD1){ref-type="supplementary-material"}).

To evaluate whether intense light-mediated increases of circulating cortisol levels ([@R48]) or temperature ([@R55]) could have caused the observed circadian amplitude enhancement, we next measured rectal temperatures or plasma cortisol levels ([@R23]) following 7 days of intense or room light housing. However, we did not observe increases in plasma cortisol levels or body temperature in intense light-exposed mice when compared with controls ([Figure S1](#SD1){ref-type="supplementary-material"}).

Altogether, these data demonstrate that intense light-elicited circadian amplitude is a cardioprotective strategy that requires PER2 and visual light perception.

Intense Light Adenosine Preconditions and Increases HIF1A-Hypoxia Response Element (HRE) Binding in the Heart before an Ischemic Insult {#S4}
---------------------------------------------------------------------------------------------------------------------------------------

Next, we deciphered the mechanism of intense light-elicited cardiac circadian amplitude enhancement and cardioprotection. First, we evaluated the effect of intense light on infarct sizes or circulating troponin-I levels at ZT15, because one week of intense light housing had increased cardiac PER2 protein levels significantly more at ZT15 (9 p.m.) compared with ZT3 (9 a.m.) ([Figure 1G](#F1){ref-type="fig"}). However, we only found slightly smaller infarct sizes or troponin-I levels at ZT15 compared with ZT3 ([Figure 2A](#F2){ref-type="fig"}). Thus, all subsequent studies focused on the robust cardioprotective effect observed at ZT3.

Because intense light had increased the physical activity in mice ([Figure 1E](#F1){ref-type="fig"}), we investigated the influence of voluntary wheel running ([@R57]) on the circadian amplitude and myocardial infarct sizes. In contrast to intense light exposure, however, two weeks of voluntary wheel running with a longer distance walked were necessary until we noted robust cardioprotection from myocardial ischemia ([Figure 2B](#F2){ref-type="fig"}) or a significant increase of the circadian amplitude ([Figure 2C](#F2){ref-type="fig"}). Nevertheless, the total distance achieved on the wheel inversely correlated with infarct sizes ([Figure 2D](#F2){ref-type="fig"}). We, therefore, evaluated two weeks of voluntary wheel running by *Per2*^−/−^ mice, which revealed decreased total running distance, decreased circadian amplitude, increased infarct sizes, and significant circadian disruption in *Per2*^−/−^ mice compared with wild-type controls ([Figures 2E](#F2){ref-type="fig"}--[2H](#F2){ref-type="fig"}). These findings demonstrate that PER2 is essential for driving the precise rhythmicity of circadian oscillations ([@R26]).

Because adenosine-mediated increase of cyclic AMP (cAMP) is a core component of PER2 expression and PER2-mediated ischemic preconditioning of the heart ([@R15]; [@R47]), we next evaluated whether intense light preconditioned the heart similar to ischemia. Analyzing uninjured hearts from wild-type or *Per2*^−/−^ mice after one week of intense light preconditioning, we discovered that intense light significantly increased cardiac adenosine or cAMP, which was abolished in *Per2*^−/−^ mice ([Figures 2I](#F2){ref-type="fig"} and [2J](#F2){ref-type="fig"}). Because light-elicited adenosine increase was abolished in *Per2*^−/−^ mice, and because light induction of cardiac PER2 protein required visual perception ([Figure 1K](#F1){ref-type="fig"}), these data suggest intense light-elicited adenosine as a circulating signaling molecule from the brain ([@R76]) to enhance peripheral PER2 expression.

Based on observations that PER2 initiates a switch from energy-efficient lipid to oxygen-efficient glucose metabolism during myocardial ischemia, which is pivotal to allow the myocardium to function ([@R4]), we next assessed the effect of intense light on glycolytic flux during normoxia. Using liquid chromatography-tandem mass spectrometry studies following infusion of labeled glucose (U^13^C-glucose), we found that intense light significantly increased the glycolytic flux in cardiac tissue before an ischemic event ([Figure 2K](#F2){ref-type="fig"}). We further found that intense light increased the activity of the key and rate-limiting enzyme of glycolysis (phosphofructokinase) in heart tissue or plasma in a PER2-dependent manner ([Figures 2L](#F2){ref-type="fig"} and [2M](#F2){ref-type="fig"}).

Considering that glycolysis is regulated by HIF1A under conditions of low oxygen availability ([@R33]), we next investigated whether intense light would increase cardiac HIF1A-HRE binding under normoxia and before an ischemic insult. Intense light significantly increased total cardiac HIF1A-HRE binding at ZT15 versus ZT3 when compared with room light conditions ([Figure 2N](#F2){ref-type="fig"}). Finally, myocardial ischemia and reperfusion studies of *Per2*^−/−^ mice confirmed that intense light-elicited circadian amplitude enhancement and subsequent cardioprotection were PER2 dependent ([Figures 2O](#F2){ref-type="fig"} and [2P](#F2){ref-type="fig"}).

Altogether, these studies found that intense light does not work via increases of physical activity only but instead preconditions cardiac tissue via increases of cardiac adenosine-cAMP signaling, HIF1A-HRE binding, and energy-efficient glycolysis before an ischemic insult. Furthermore, our data suggest intense light-elicited adenosine as a circulating signaling molecule ([@R76]) to enhance peripheral PER2-mediated cardioprotection.

Intense Light-Elicited Cardioprotection Is Abolished in Mice with Endothelial-Specific Deletion of *Per2* {#S5}
---------------------------------------------------------------------------------------------------------

To understand intense light-elicited and PER2-dependent pathways, we performed a genome-wide array, profiling intense light-dependent gene expression before an ischemic event. *In silico* analysis found dominant regulation of circadian and metabolic pathways ([Figure 3A](#F3){ref-type="fig"}) and identified the hypoxia/HIF1A-regulated and metabolic key player angiopoietin-like 4 (ANGPTL-4) as the top light and PER2-dependent gene ([Figure 3B](#F3){ref-type="fig"}), supporting our findings that intense light-elicited PER2 activates HIF1A-regulated pathways under normoxic conditions. Because ANGPTL-4 is an endothelial secreted protein that protects endothelial barrier function during myocardial ischemia ([@R19]), we next evaluated endothelial-specific *Per2* deletion during myocardial ischemia and reperfusion (IR) injury. Using a tissue-specific mouse line with 70% deletion of PER2 in the endothelium ([Figure 3C](#F3){ref-type="fig"}, *Per2^loxP/loxP^*-VE-Cadherin-Cre; [Figure S2](#SD1){ref-type="supplementary-material"}), we found significantly increased infarct sizes and troponin-I serum levels in *Per2^loxP/loxP^*-VE-Cadherin-Cre ([Figures 3D](#F3){ref-type="fig"}--[3F](#F3){ref-type="fig"}). Intense light-elicited cardioprotection was abolished in *Per2^loxP/loxP^*-VE-Cadherin-Cre mice. Because these data implicated intense light in maintaining vascular integrity during myocardial IR injury, we determined the vascular leakage of Evans blue dye following 7 days of room light or intense light housing. As shown in [Figures 3G](#F3){ref-type="fig"}--[3I](#F3){ref-type="fig"}, intense light pretreatment significantly improved endothelial barrier function during myocardial IR injury, which was abolished in endothelial-specific *Per2*^−/−^ mice.

Studies identified adenosine signaling via the adenosine A2B receptor (ADORA2B) as a crucial pathway for PER2 stabilization during myocardial ischemia ([@R15]). Because intense light had increased cardiac adenosine levels, we questioned whether ADORA2B-mediated adenosine signaling could be the signaling link between the brain and the heart. Our data revealed abolished intense light therapy-mediated improvement of endothelial barrier function in *Adora2b*^−/−^ mice ([Figure 3J](#F3){ref-type="fig"}).

Considering that intense light had increased HIF1A-HRE binding at ZT15, we next evaluated HIF1A binding to the promoter region of mouse *Angptl4* at ZT15. Evaluation of mouse *Angptl4* promoter regions identified several HRE binding sites ([Figure S3](#SD1){ref-type="supplementary-material"}), and subsequent chromatin immunoprecipitation (ChIP) assays demonstrated significantly increased HIF1A binding in two promoter regions ([Figure 3K](#F3){ref-type="fig"}).

Altogether, these data identify endothelial-specific PER2 as a mechanism of intense light-elicited cardioprotection and suggest intense light as a strategy to improve endothelial barrier function via increase of adenosine-ADORA2B signaling and HIF1A transcription.

Endothelial PER2 Is Critical for Transcriptional Control of HIF1A-Dependent Glycolysis {#S6}
--------------------------------------------------------------------------------------

Based on our findings for a vital role of endothelial-specific PER2 in intense light-mediated cardioprotection and endothelial barrier protection during myocardial IR injury *in vivo,* we next evaluated endothelial PER2 signaling targets during hypoxia *in vitro.* For this purpose, we generated a lentiviral-mediated PER2 knockdown (KD) stable cell line in human microvascular endothelial cells (HMECs, specifically HMEC-1). Similar to previous studies of PER2 gene-targeted mice ([@R15]), hypoxia increased PER2 transcript or protein levels in HMEC-1 scrambled (Scr) controls, whereas PER2KD HMEC-1 displayed abolished transcriptional induction of HIF1A-dependent glycolytic enzymes, attenuated lactate production, reduced glycolytic capacity, and increased cytotoxicity ([Figure S4](#SD1){ref-type="supplementary-material"}). Based on observations in HMEC-1 that PER2 is significantly increased 24 h after cell synchronization when compared with the 12 h time point ([@R15]), we determined whether oscillatory higher PER2 levels would affect metabolism under normoxic conditions. These studies revealed a significant increase of glycolytic capacity in control HMEC-1 compared with PER2KD cells at the 24 h time point ([Figure S4](#SD1){ref-type="supplementary-material"}). Mechanistic studies using a ChIP assay uncovered hypoxia-induced HIF1A binding to the human lactate dehydrogenase promotor region, a response that was abolished in PER2KD cells ([Figure S4](#SD1){ref-type="supplementary-material"}).

Altogether, these findings uncover a critical role for endothelial PER2 in cellular metabolic adaption under normoxia or hypoxia and reveal endothelial PER2 as an essential cofactor of HIF1A-mediated transcription of glycolytic genes and thus a key regulator of glycolytic metabolism.

Identification of Endothelial PER2 as a Regulator of Tricarboxylic Acid (TCA) Cycle Activity {#S7}
--------------------------------------------------------------------------------------------

Because hypoxia increased PER2 protein like intense light, we next used an unbiased affinity purification-mass spectrometry-based proteomics screen for PER2 protein interactions under hypoxic conditions to gain a deeper mechanistic perspective of endothelial PER2-dependent mechanisms ([Figure 4A](#F4){ref-type="fig"}; [Figure S5](#SD1){ref-type="supplementary-material"}; [Table S1](#SD2){ref-type="supplementary-material"}). Serendipitously, a high percentage of PER2-protein interactions hinted at an essential role for PER2 in controlling TCA cycle function ([Figure 4B](#F4){ref-type="fig"}). Subsequent coimmunoprecipitation (coIP) pull-downs on TCA cycle enzymes confirmed binding to PER2 during hypoxia ([Figures 4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}). Subsequent analyses of subcellular compartments found that hypoxia increased PER2 protein levels in the cytoplasm, nucleus, and mitochondria ([Figure 4E](#F4){ref-type="fig"}). Thus, PER2 protein interactions may facilitate the transport of mitochondrial proteins, which are almost exclusively synthesized in the cytosol. Our proteomics screen indicated PER2 binding to the mitochondrial outer membrane translocase (Tom) complex ([Table S1](#SD2){ref-type="supplementary-material"}; [@R17]), which is the main protein entry gate of mitochondria ([@R6]). Subsequent colocalization studies confirmed PER2 translocation into the mitochondria during hypoxia ([Figure 4F](#F4){ref-type="fig"}; [Figure S6](#SD1){ref-type="supplementary-material"}). Functional assays on TCA cycle enzyme activity revealed regulation of TCA cycle function during hypoxia in a PER2-dependent manner ([Figures 4G](#F4){ref-type="fig"}--[4I](#F4){ref-type="fig"}), and hypoxic PER2KD cells showed significantly less CO~2~ production, a surrogate endpoint of TCA cycle function ([Figure 4J](#F4){ref-type="fig"}).

Considering that TCA cycle enzyme activity is also known to be regulated by Sirtuin3 (SIRT3)-mediated de-acetylation ([@R73]), which is under circadian control ([@R50]), we investigated whether hypoxia- and HIF1A-PER2-dependent pathways would regulate SIRT3 expression. HMEC-1 transcriptional or translational analyses with a PER2 or HIF1AKD revealed PER2-HIF1A-dependent regulation of SIRT3 under hypoxic conditions ([Figures 4K](#F4){ref-type="fig"}--[4M](#F4){ref-type="fig"}; [Figure S7](#SD1){ref-type="supplementary-material"}). *In silico* analysis confirmed a HRE in the human promoter region of SIRT3 ([Figure S7](#SD1){ref-type="supplementary-material"}).

Altogether, our proteomics screen uncovered a critical role for endothelial PER2 in controlling oxidative TCA cycle metabolism during hypoxia by translocating into the mitochondria and via transcriptional regulation of HIF1A-SIRT3-dependent pathways. These data suggest a more complex function of PER2, possibly controlling the TCA cycle function via post-translational mechanisms.

Endothelial PER2 Transcriptionally Regulates Mitochondrial Respiration and Barrier Function {#S8}
-------------------------------------------------------------------------------------------

Additional analysis of our proteomics screen indicated binding of PER2 to mitochondrial complex 4 ([Table S1](#SD2){ref-type="supplementary-material"}, cytochrome c), supporting a role for PER2 in controlling mitochondrial function under hypoxia. Oxygen consumption rate (OCR, a measure of mitochondrial functionality), basal respiration, maximal respiration, ATP production, and spare capacity were significantly reduced in PER2KD cells during a mitochondrial stress test ([Figures 5A](#F5){ref-type="fig"}--[5D](#F5){ref-type="fig"}; [Figure S7](#SD1){ref-type="supplementary-material"}). Moreover, OCR levels were significantly increased in cells with higher PER2 levels at the 24 h time point when compared with 12 h post-cell synchronization ([@R15]). These findings highlight a role for oscillatory PER2 overexpression in metabolic adaptation under normoxia ([Figure S7](#SD1){ref-type="supplementary-material"}).

Considering that HIF1A mediates a switch of complex 4 subunits (COX4.1 to COX4.2) in hypoxia to enhance oxygen efficiency, which conserves cellular ATP content ([@R18]), we next investigated the transcriptional regulation of COX4.2 in PER2KD cells under hypoxia. Here, we found abolished increases of COX4.2 mRNA or complex 4 activity in hypoxic PER2KD cells or ischemic hearts from *Per2*^−/−^ mice, respectively ([Figures 5E](#F5){ref-type="fig"} and [5F](#F5){ref-type="fig"}). Moreover, intense light preconditioning of wild-type mice resulted in significantly increased cardiac COX4.2 mRNA levels at ZT3 in the uninjured heart ([Figure 5G](#F5){ref-type="fig"}).

To understand whether compromised oxidative phosphorylation in PER2 deficiency would be associated with reduced mitochondrial membrane potential, which is associated with compromised mitochondrial function ([@R61]), we next used MitoTracker deep red staining ([@R78]). Studies of PER2KD HMEC-1 indicated already reduced mitochondrial potential under normoxia ([Figure 5H](#F5){ref-type="fig"}). Analysis of a cell energy phenotype assay revealed significantly less aerobic metabolism in PER2KD cells at baseline ([Figure S8](#SD1){ref-type="supplementary-material"}). Confirming these results, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimi-dazolcarbocyanine iodide (JC-1) assay showed a significant reduction of the membrane potential in PER2KD cells at normoxia and under hypoxia ([Figure 5I](#F5){ref-type="fig"}; [Figure S8](#SD1){ref-type="supplementary-material"}).

To explore PER2-dependent metabolism, we next used liquid chromatography-tandem mass spectrometry studies following the exposure of labeled glucose (^13^C-fructose) or labeled palmitic acid (^13^C-palmitic acid) to assess metabolic flux in PER2KD endothelial cells. Here we confirmed that PER2 is an essential regulator of glycolysis and oxidative metabolism under hypoxia ([Figures 5J](#F5){ref-type="fig"} and [5K](#F5){ref-type="fig"}). Moreover, we found PER2 to be critical for the pentose phosphate pathway under normoxia or hypoxia, indicating that PER2KD cells are compromised in generating the reduction-oxidation reaction (redox) cofactor NADPH, which has a pivotal role for circadian timekeeping ([Figure 5L](#F5){ref-type="fig"}) ([@R52]). Because PER2 has been shown to inhibit lipid metabolism via peroxisome proliferator-activated receptor gamma (PPARγ) ([@R24]), we also found altered fatty acid metabolism in PER2KD cells under hypoxia ([Figure 5M](#F5){ref-type="fig"}). *In silico* analysis of our proteomics screen confirmed these findings and highlighted PER2 as a master regulator of endothelial energy metabolism ([Figure S9](#SD1){ref-type="supplementary-material"}).

Because ATP has been implicated in endothelial barrier enhancement and tight junction functionality ([@R32]), we next evaluated endothelial barrier function of PER2KD HMECs and controls during a 24 h hypoxia time course. As shown in [Figure 5N](#F5){ref-type="fig"}, PER2KD HMEC demonstrated increased cell permeability at 2, 4, 6, 12, and 24 h of hypoxia when compared with Scr controls. Considering that previous studies had demonstrated that HIF-dependent regulation of claudin-1 is central to epithelial tight junction integrity ([@R53]), we also evaluated claudin-1 expression levels. As shown in [Figure 5O](#F5){ref-type="fig"}, PER2KD cells had significantly lower HIF1A-regulated *Claudin-1* mRNA levels. In addition, intense light preconditioning of wild-type mice resulted in significantly increased cardiac *Claudin-1* mRNA levels at ZT3 ([Figure 5P](#F5){ref-type="fig"}).

Altogether, these data identify endothelial PER2 as a critical control point of energy homeostasis and endothelial barrier function via transcriptional regulation of HIF1A-dependent mitochondrial respiration and claudin-1.

A Light-Sensing Human Endothelial Cell Line Recapitulates *In Vivo* Light Exposure {#S9}
----------------------------------------------------------------------------------

As proof of concept that PER2 mimics HIF1A pathways under normoxia, we reiterated light sensing for PER2 overexpression on a cellular level by generating an HMEC-1 line overexpressing the human light-sensing photopigment melanopsin (OPN4), a retinal ganglion cell receptor responsible for circadian entrainment. Exposing the light-sensing HMEC-1 cultures to light resulted in asignificant increase of cAMP, pCREB (phosphorylated cAMP-responsive element binding protein), PER2 mRNA, glycolytic capacity, and OCRs ([Figures 6A](#F6){ref-type="fig"}--[6H](#F6){ref-type="fig"}). Altogether, these studies recapitulate that normoxic PER2 overexpression can optimize cellular metabolism similar to what is seen under hypoxic conditions.

In summary, our *in vivo* and *in vitro* studies on light-elicited pathways identified a light perception-dependent circadian entrainment mechanism through adenosine-cAMP and HIF1A transcriptional adaptation in a PER2-regulated manner. Furthermore, our studies discover that light or hypoxia elicits PER2 as a critical factor in maintaining endothelial barrier function during myocardial ischemia via transcriptional reprogramming ([Figure 6I](#F6){ref-type="fig"}).

Intense Light Enhances the Circadian Amplitude and PER2-Dependent Metabolism in Humans {#S10}
--------------------------------------------------------------------------------------

Next, we investigated whether intense light would have similar effects on healthy human volunteers. Based on strategies using intense light therapy (10,000 lux) to treat seasonal mood disorders in humans ([@R72]), we adopted a similar protocol. We exposed healthy human volunteers to 30 min of intense light in the morning on 5 consecutive days and performed serial blood draws. Intense light therapy increased PER2 protein levels in human buccal or plasma samples in the morning (9 a.m.) or evening (9 p.m.), indicating an enhancement of the circadian amplitude in different tissues at the same time via light therapy ([Figures 7A](#F7){ref-type="fig"}--[7C](#F7){ref-type="fig"}; [Figure S10](#SD1){ref-type="supplementary-material"}). To test the efficacy of intense light therapy on the circadian system ([@R37]), we determined melatonin plasma levels, which were significantly suppressed upon light treatment ([Figures 7D](#F7){ref-type="fig"} and [7E](#F7){ref-type="fig"}). In addition, room light was less efficient than intense light therapy in suppressing melatonin ([Figure 7D](#F7){ref-type="fig"}).

Further analyses revealed that intense light therapy increased plasma phosphofructokinase at 9 a.m. or 9 p.m. ([Figures 7F](#F7){ref-type="fig"} and [7G](#F7){ref-type="fig"}). Moreover, plasma triglycerides, surrogates for insulin sensitivity and carbohydrate metabolism ([@R21]), significantly decreased upon light therapy ([Figure 7H](#F7){ref-type="fig"}), indicating increased insulin sensitivity and glucose metabolism. Targeted metabolomics from human plasma samples confirmed a strong effect of light therapy on metabolic pathways such as glycolysis or the TCA cycle ([Figure 7I](#F7){ref-type="fig"}; [Figure S10](#SD1){ref-type="supplementary-material"}). We found significant decreases in pyruvate or succinate levels after 5 days of light therapy ([Figures 7J](#F7){ref-type="fig"} and [7K](#F7){ref-type="fig"}). Together with increased plasma phosphofructokinase activity, this finding indicates that improved metabolic flux, possibly because of increased glycolysis, improved TCA cycle or mitochondrial function.

Because sleep deprivation is directly associated with decreased insulin sensitivity and compromised glucose metabolism ([@R10]), we next determined how light therapy would affect human physiology in terms of sleep behavior. Using a validated accelerometer for actigraphy ([@R35]) (Actiwatch 2), we found fewer WASO (wake after sleep onset) episodes, overall improved sleep efficiency, increased day activity, and increases of the circadian amplitude ([Figures 7L](#F7){ref-type="fig"}--[7P](#F7){ref-type="fig"}; [Figure S11](#SD1){ref-type="supplementary-material"}).

Altogether, our data suggest that intense light therapy, a mechanism of circadian amplitude enhancement, targets PER2-dependent metabolic pathways in humans that are similar to those seen in mice and may present a promising strategy for the treatment or prevention of low-oxygen conditions such as myocardial ischemia.

DISCUSSION {#S11}
==========

Our studies established a critical role for intense light in regulating critical biological processes ([@R74]). Epidemiological studies noting an increase in myocardial infarctions (MIs) during the darker winter months in all U.S. states ([@R62]) support our conclusion that intense light elicits robust cardioprotection. The mechanism of how the entrainment signal gets to peripheral organs remains unclear but may incorporate neuro-hormonal factors, or autonomic innervation ([@R63]). Studies on altered liver metabolism in constant darkness found adenosine to be a possible circulating circadian factor ([@R76]), which suggests adenosine signaling as a mechanism for establishing circadian rhythmicity between peripheral organs and suprachiasmatic nuclei (SCNs). The importance of adenosine signaling via the ADORA2B for cAMP increases, PER2 stabilization, and cardiac metabolic adaption to ischemia has been shown in studies investigating the mechanism of myocardial ischemic preconditioning ([@R15]). In our studies, we found that light increased cardiac adenosine and cAMP levels under normoxia, which was also PER2 dependent. Although we did not determine plasma adenosine levels, we were able to detect adenosine increases in blood containing and flash-frozen mouse hearts. Because intense light pretreatment did not improve endothelial barrier function in *Adora2b*-deficient mice, adenosine signaling might play an essential role in transmitting the cardioprotective light signal from the SCNs to the heart. However, because our studies are limited to observations in wild-type, whole-body *Adora2b*^−/−^ or *Per2*^−/−^ and endothelial-specific *Per2*-deficient mice, future studies will be necessary to investigate the brain-specific role of adenosine signaling in peripheral PER2 stabilization.

Although cardiomyocytes are significant oxygen consumers and account for approximately 75% of the myocardial volume, there is at least one capillary adjacent to every cardiomyocyte, and cardiomyocytes are outnumbered 3:1 by endothelial cells ([@R7]). Mitochondrial metabolism in endothelial cells has been proposed as a central oxygen sensor in the vasculature ([@R9]), and studies have suggested that human endothelial cells can regulate the activity of HIF1A, thus affecting key response pathways to hypoxia and metabolic stress ([@R9]). As such, endothelial dysfunction plays a significant role in myocardial IR injury, rendering endothelial cells an attractive target for myocardial protection ([@R70]). In our studies, we uncovered a critical role for light-elicited PER2 in controlling endothelial barrier function. Although PER2 has been implicated in endothelial function in previous studies ([@R67]; [@R68]), an endothelial-specific role of PER2 during acute myocardial IR injury, which can be targeted using intense light, has not yet been described. Moreover, our *in vivo* and *in vitro* studies suggest that light-elicited transcriptional reprogramming of endothelial cells protects endothelial barrier function during IR injury. Together with previous studies on myocardial IR injury ([@R70]), these studies highlight the importance of cardiac endothelia in IR injury and point toward unrecognized therapeutic strategies for cardiovascular disease using intense light or pharmacological compounds, such as the circadian rhythm enhancer nobiletin ([@R20]; [@R49]), to increase the amplitude of endothelial PER2. Despite this strong evidence, our studies are limited to analysis of endothelia-specific PER2-deficient mice; thus, the contribution of other cardiac cells cannot be fully excluded ([@R60]).

The importance of HIF1A in cardioprotection has been shown in numerous studies ([@R59]), and the interaction between HIF1A and PER2 has been demonstrated on the protein level ([@R15]; [@R30]) and the transcriptome level ([@R69]), In general, HIF1A requires hypoxic conditions to be stabilized ([@R59]). In our studies, we established the dependence of HIF1A on PER2 as a transcription factor during hypoxia, supporting previous studies on PER2 function as an effector molecule for the recruitment of HIF1A to promoter regions of its downstream genes ([@R30]). However, we also found that specific HIF1A pathways that control glycolysis, mitochondrial respiration (COX4.2), or endothelial barrier function (ANGPTL-4/claudin-1 \[CLDN1\]) can be transcriptionally activated via light-elicited circadian overexpression of PER2 under normoxia. These findings would suggest that PER2 amplitude enhancement strategies can precondition the myocardium by establishing a HIF1A-similar signaling environment before an ischemic event. Although the role of CLDN1 or COX4.2 in cardioprotection has not been investigated yet, studies have shown the importance of endothelial-expressed HIF1A in ischemic preconditioning of the heart ([@R54]). Limitations of these findings include that we did not investigate these pathways in endothelial-specific *Per2*- or *Hifa*-deficient mice. Furthermore, the mechanism by which light or hypoxia facilitates a PER2-HIF1A interaction remains elusive. Future genetic studies using tissue-specific mice or CRISPR technology to manipulate specific PER2 or HIF1A sequences ([@R56]) will be necessary to understand the role of these pathways and its mechanisms in intense light-elicited cardioprotection.

Given a close association of circadian amplitude dampening and disease progression ([@R22]), clock-enhancing strategies are promising approaches for disease treatment. Although it is well known that light regulates circadian rhythms ([@R8]) and that high intensities of light are more effective for circadian entrainment and amplitude enhancement ([@R37]), only a few reports exist on circadian entrainment and cardioprotection ([@R40]). Although previous studies suggested that short-term intense light exposure could mediate cardioprotection in a PER2-dependent manner ([@R15]), no specific mechanisms had been provided. In our studies, we uncovered that intense light increases the circadian amplitude in a PER2-dependent manner that appeared to be more efficient than exercise-induced amplitude enhancement. This finding could have implications for clinical practice in which exercise limitations or lack of motivation for exercise is commonly observed. However, because we did not investigate blindness in endothelial-specific PER2-deficient mice or evaluate different time points for PER2 expression in our blind mice, future studies will be necessary to fully elucidate the role of circadian PER2 amplitude enhancement in cardioprotection.

Our light exposure strategy in humans showed kinetics similar to those seen in mice, which could be explained by the circadian rhythms functioning independently of a diurnal or nocturnal behavior because of multiple yet parallel outputs from the SCNs ([@R34]). Basic features of the circadian system are the same in apparently diurnal and nocturnal animals, including the molecular oscillatory machinery and the mechanisms responsible for pacemaker entrainment by light ([@R34]). In addition, PER2 is hypoxia-regulated in mice and humans, which supports similar mechanisms in both species ([@R15]). HIF1A regulation and function under hypoxia, which is strongly associated with PER2 ([@R30]), also seems to be independent of a nocturnal nature ([@R59]), despite HIF1A expression being under circadian control ([@R69]). Human and mouse studies on HIF1A find similar responses to cardiovascular ischemic events ([@R59]). Nevertheless, differences in size and physiology, as well as variations in the homology of targets between mice and humans, may lead to translational limitations.

Supporting the importance of circadian rhythms in myocardial susceptibility to ischemia, studies found a diurnal pattern for troponin values in patients undergoing aortic valve replacement ([@R43]). Here, troponin values following surgery were significantly higher in the morning when compared with the afternoon. Although nothing can be done about a diurnal pattern, applying light therapy before high-risk non-cardiac or cardiac surgery to enhance the circadian amplitude might be able to provide robust cardioprotection. Light-elicited circadian amplitude enhancement suggests an overall increase in PER2 levels and concomitant cardioprotection even at the trough of the amplitude, indicating that this strategy could promote general cardioprotection and potentially decrease troponin levels in both morning and evening times. However, future studies of humans will be necessary to understand the impact of intense light therapy and its potential role in cardioprotection.

STAR★METHODS {#S12}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S13}
---------------------------------------

Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Tobias Eckle (<tobias.eckle@cuanschutz.edu>). Mouse and cell lines generated in this study are available upon request via a material transfer agreements (MTA).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S14}
--------------------------------------

### Mouse experiments {#S15}

Experimental protocols were approved by the Institutional Review Board (Institutional Animal Care and Use Committee \[IACUC\]) at the University of Colorado Denver, USA. They were in accordance with the NIH guidelines for the use of live animals. *All mice were housed in a 14 h (hours):10 h L(light):D(dark) cycle and we routinely used age-matched 12- to 16-week old male mice.* All mice had a C57BL/6J background. C57BL/6J, *Per2*^−/−^\[Per2tm1Brd Tyrc-Brd/J ([@R77])\], and PER2 luciferase \[B6.129S6-*Per2^tm1Jt^*/J ([@R71])\] mice were purchased from Jackson laboratories. *Per2^loxp/loxp^* and *Adorab2^loxp/loxp^* ([@R60]) mice were generated by Ozgene (Perth, Australia). VE-Cadherin-Cre \[B6.Cg-Tg(Cdh5-cre)7Mlia/J([@R3])\] or Germline Cre \[B6.C-Tg(CMV-cre)1Cgn/J\] were purchased from Jackson laboratories. To obtain endothelial tissue-specific mice, we crossbred *Per2^loxp/loxp^* mice with the VE-Cadherin-Cre recombinase mouse. To obtain *Adora2b*^−/−^ mice we crossbred *Adorab2^loxp/loxp^* with the Germline Cre mouse. Before experiments, mice were housed for at least 4 weeks in a 14/10-h light-dark (lights on 6 AM \[ZT0\], lights off 8 PM\[ZT14\]) cycle to synchronize (entrain) the circadian clock of all mice to the ambient light-dark cycle. We conducted all mouse experiments at the same time points (ZT 3, ZT15), unless specified otherwise.

### Human subjects {#S16}

Healthy human volunteers were exposed to intense light exposure (10,000 LUX) for 30 min every morning for five days from 8:30 AM -- 9:00 AM. 5 mL blood was drawn on day one at 8:30 AM and 9:00 AM (before and after light exposure). We obtained approval from the Institutional Review Board (COMIRB \#13-1607) for our human studies prior to written informed consent from everyone. A total of 17 healthy volunteers were enrolled (11 female and 6 male, age range between 21-44 years.).

METHOD DETAILS {#S17}
--------------

### Intense light exposure in mice {#S18}

Mice were exposed to intense light (10,000 LUX, Lightbox, Uplift Technologies DL930, full spectrum, UV filter) for 3, 5 or 7 days and compared to mice maintained at room light \[200 LUX\] for 7 days *(**Note**: infarct sizes are always the same atZT3 (9AM) regardless of the length of being housed under normal housing conditions)* ([@R5]). To control for temperature changes, we measured the rectal temperature, using a rectal thermometer probe (RT, Effenberg, Munich, Germany).

### Cortisol measurements {#S19}

To measure plasma cortisol levels in mice after one week of room light or intense light a mouse cortisol ELISA Kit (LifeSpan BioSciences, Inc., Seattle, WA) was used.

### Murine model for cardiac MI and heart enzyme measurement {#S20}

Murine *in situ* myocardial ischemia and reperfusion injury *(60-min ischemia/120 min reperfusion)* and troponin-I (cTnI) measurements were performed as described ([@R11],[@R12],[@R14]). Infarct sizes were determined by calculating the percentage of infarcted myocardium to the area at risk (AAR) using a double staining technique with Evan's blue and triphenyltetrazolium chloride. AAR and the infarct size were determined via planimetry using the NIH software Image 1.0 (National Institutes of Health, Bethesda, MA). For troponin I (cTnI) measurements blood was collected by central venous puncture and cTnI was analyzed using a quantitative rapid cTnI assay (Life Diagnostics, Inc., West Chester, PA, USA). ***Note***: *cTnI is highly specific for myocardial ischemia and has a well-documented correlation with the infarct size in mice* ([@R11], [@R12], [@R13]; [@R31]) *and humans* ([@R66]).

### Wheel running {#S21}

Mice were maintained individually in running-wheel cages (Starr Life Sciences, wheel diameter: 11.5 cm). Running-wheel activity was recorded every 5 minutes using the Vital View Data Acquisition System (Starr Life Sciences, Oakmont, PA). Data were analyzed using BioDare (Biological Data Repository) ([@R44]). Amplitude of wheel running activity was calculated using the fast fourier transform non-linear least-squares (FFT-NLLS) method. The distance walked was calculated as the sum of a 7 day-recording.

### Luciferase Assay {#S22}

Expression of the PER2 protein using luciferase reporter mice was assayed as described ([@R15]). Expression of the PER2 protein using luciferase reporter mice was determined using the tissue homogenates in T-per Tissue Protein Extraction Reagent (Pierce, Thermo Fisher Scientific, Waltham, MA). The homogenates were centrifuged for 30mins at 4900 × g at 4°C. The luciferase protein activity was measured by using the Dual-Luciferase Reporter Assay System from Promega according to the manufacturer's instructions using a Biotek Synergy 2 Multimode Microplate Reader (Winooski, VT).

### Enucleation procedure in mice {#S23}

Mice were pre-anesthetized with subcutaneous carprofen and buprenorphine injections and anesthetized with a ketamine/xylazine/ace cocktail. The periocular region was then clipped to remove surrounding hair. After a surgical scrub with betadine, the optic nerve and associated blood vessels were clamped with hemostats. After 2 minutes the entire globe of eye and the optic nerve were removed. For additional analgesia bupivacaine was dripped into the socket. Next, the complete upper and lower eyelid margin were removed with fine tip scissors and the eyelids were closed with 3-4 interrupted sutures. Mice were recovering in cages on warm water circulating blankets. Carprofen injections were repeated every 24 hours for 2 days post operatively. After a 2-week recovery period under standard housing conditions, mice underwent intense light housing or myocardial ischemia studies.

### ^13^*C-tracers* in vivo {#S24}

C57BL/6 wild-type mice were housed under daylight (10,000 LUX, L:D 14:10 h) or standard room light (200 LUX, L:D 14:10 h) for 7 days followed by infusion of 10 mg/kg/min U-^13^C-glucose (Cambridge Isotope Laboratories, Tewksbury, MA) via an intra-arterial catheter over 90 minutes. Left ventricles of the hearts were flushed with ice cold KCl and the left ventricle was shock frozen and analyzed by liquid chromatography-tandem mass spectrometry. Isotope-resolved metabolite analyses were performed by LC-MS on a Waters Acquity ultrahigh-performance liquid chromatography (UPLC) system coupled to a Waters Synapt HDMS quadrupole time-of-flight mass spectrometer equipped with an atmospheric pressure electrospray ionization (ESI) source. LC-MS was performed with full-mass detection within m/z 100-1000 in the positive-ion or negative-ion mode as described below. The typical MS operation parameters included ESI spray voltage 2.8 kV, sampling cone voltage 4 V, drying gas flow 50 L/min / temperature 120°C, and nebulizing nitrogen gas flow 700 L/h / temperature 350°C. The authentic compound sodium D-fructose-6-sphosphate was obtained from Sigma-Aldrich and were used as the standard substances for location and identification of the targeted metabolites. UPLC conditions were optimized to ensure appropriate separation of each metabolite from its structural isomers and the interfering components detected in the samples. For sample preparation, frozen specimens were individually ground to fine powder in liquid nitrogen and were weighed to 5-mL borosilicate glass test tubes. Ice-cold methanol-water (50:50, v/v), equivalent to 1 mL per 100 mg tissue, was added to each tube. The samples were lysed on ice with 15 s × 2 sonications using a Fisher Scientific Model 100 cell dismembrator. After vortex-mixing and 5-min sonication in an ice-water bath, ice-cold methanol, equivalent to 1 mL per 100 mg tissue, was added. The sample tubes were capped, violently vortex-mixed for 2 min, sonicated in the same ice-water bath for 5 min and then placed at ‒20°C for 2 h. before the tubes were centrifuged at 4,000 rpm and 4°C for 15 min in a Beckman Coulter Allegra X-22R centrifuge. The clear supernatant of each sample was collected and transferred to a 3-mL borosilicate glass test tube for the following LC-MS analyses. Fructose-6-phosphate was measured by ion-pairing LC-MS using tributylamine (TBA) as the paired counterion reagent.([@R39]) The chromatographic separation was conducted on a YMC-Triart C18 UPLC column (2.1 × 150 mm, 1.9 μm) using binary-solvent gradient elution with 2 mM TBA in water (pH adjusted to 6 with acetic acid) as mobile phase A and methanol as mobile phase B. The elution gradient was 0-9 min, 2% to 55% B; 9-9.5 min, 55% to 100% B; 9.5-- 11 min, 100% B. The column was equilibrated with 2% B for 5 min between injections. The column flow rate was 0.25 mL/min and the column temperature were 50°C. A 100 μL aliquot of each supernatant from individual mouse heart specimens was dried under a nitrogen flow in a fume hood and the residue was reconstituted in 200 μL of mobile phase A. 5 μL was injected for LC-MS with negative-ion detection. The organic acids were analyzed by chemical derivatization LC-MS with 3-nitrophenyl hydrazine (3NPH) as the pre-analytical derivatizing reagent.([@R27]) In brief, 100 μL of the supernatant was mixed 50 μL of 200 mM 3NPH.HCl in 75% methanol and 50 μL of 150 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-HCl. The mixture could react at 30°C for 30 min and was then mixed with 400 μL of water. 10 μL aliquots were injected onto a C8 UPLC column (2.1 × 50 mm, 1.7 μm) for LC-MS runs with negativeion detection and using the LC procedure as described.([@R27]) For all the above LC-MS analyses, the monoisotopic ion chromatograms of the metabolite, together with their isotopomeric counterparts resulting from the U-^13^C glucose tracer, were extracted based on their calculated m/z values, within a mass window of 60 ppm (+/− 30 ppm), and their peak areas were integrated. The peak areas of any observed isotopomeric forms derived from the U-^13^C glucose tracer for the metabolite was corrected by subtracting the abundance contributions from the natural and any other U-^13^C glucose tracer-derived isotopic forms ([@R15], [@R16]; [@R27], [@R28]).

### PFK and cAMP-activity mouse tissue {#S25}

To measure Phosphofructokinase activity from myocardium or plasma, C57BL/6J or *Per2*^−/−^ mice were euthanized following light exposure. Blood was removed to obtain plasma further analysis, and the tissue was immediately flash frozen at −80°C. Enzyme activity from homogenized tissue or plasma was determined using a PFK Assay Kit from Biovison. To determine cAMP in cardiac tissue, a cyclic AMP Enzyme Immunoassay Kit (Mouse/Rat cAMP Parameter Assay Kit, R&D, Minneapolis, MN) was used according to the manufacturer's protocol.

#### Adenosine measurements {#S26}

Whole murine hearts were collected in 1 mL of 80% MeOH and flash-frozen under liquid nitrogen and stored at −80°C. Adenosine was extracted and quantified in the tissue as described ([@R36]). Analyses were performed on an Agilent Technologies 1260 Infinity HPLC using a phenomenex Luna C18(2) column (100 Å, 150 X 4.6 mm) (mobile phase A: 50 mM KH2PO4, 5 mM tetrabuty-lammonium bisulfate, pH 6.25; mobile phase B: acetonitrile; column temperature: 30°C; flow rate: 1 mL/min; 75 μL injection). Samples were filtered through VIVASPIN 500 membranes (Sartorius Stedim Biotech, 5,000 MWCO, PES) prior to HPLC analysis. Chromatographic separation of the metabolites was performed using a combination of isocratic and gradient methods including column washing and equilibration periods at the end (0 min: 100% A; 7 min: 100% A; 10 min: 97% A; 18 min: 97% A; 45 min: 86% A; 60 min: 50% A; 80 min: 50% A; 90 min: 100% A; 135 min: 100% A). Adenosine was detected by absorption at 254 nm, and the absorbance spectra and retention time verified by co-injection with an authentic standard.

### HIF1A-HRE binding assay {#S27}

Nuclear protein fractions were isolated from heart tissue using NE-PER kit following the manufacturer's instructions (Thermo Fisher Scientific, Waltham, MA). Protein was quantified using the BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA). HIF1A transcription factor from 20 μg of nuclear protein was measured using a HIF1A Transcription Factor Assay kit (Abcam, ab133104, Cambridge, MA).

### Microarray analysis {#S28}

Total RNA was isolated from heart tissue from intense light or room light 'pretreated' C57BL/6J or *Per2*^−/−^ mice with the RNeasy micro kit (QIAGEN, Valencia, CA) using QIAGEN on-column DNase treatment to remove any contaminating genomic DNA. The integrity of RNA was assessed using a Tapestation 2200 (Agilent Technologies) and RNA concentration was determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop, Rockland, DE). Hybridization cocktail was prepared starting with 100ng Total RNA using the GeneChip WT PLUS Reagent Kit. Samples were hybridized to the Arrays (Mouse Clariom D arrays) for 16 hours at 45°C in a GeneChip Hybridization Oven 645. Arrays were then washed and stained in a GeneChip Fluidics Station 450 and scanned in a GeneChip Scanner 3000. Each array was subjected to visual inspection for gross abnormalities. Several other QC metrics were used to monitor hybridization efficiency and RNA integrity over the entire processing procedure. Raw image files were processed using Affymetrix GCOS 1.3 software to calculate individual probe cell intensity data and generate CEL data files. Using GCOS and the MAS 5.0 algorithm, intensity data was normalized per chip to a target intensity TGT value of 500 and expression data and present/absent calls for individual probe sets calculated. Gene symbols and names for data analyzed with the MAS 5.0 algorithm were from the Affymetrix NetAffx Mouse 430_2 annotations file. Quality control was performed by examining raw DAT image files for anomalies, confirming each GeneChip array had a background value less than 100, monitoring that the percentage present calls was appropriate for the cell type, and inspecting the poly (A) spike in controls, housekeeping genes, and hybridization controls to confirm labeling and hybridization consistency. According to our experimental setup the arrays were normalized, grouped and analyzed for differentially expressed transcripts based on different statistical tests. Different clustering algorithms allowed us to identify transcripts that show similar expression profiles. Using the TAC (Transcriptome Analysis Console, Affymetrix) software we were able to identify biological mechanisms, pathways and functions most relevant to our experimental dataset. Array data have been deposited in the Array Express database at EMBL-EBI (<https://www.ebi.ac.uk/arrayexpress/>) under accession number E-MTAB-7196 (<http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7196>).

### Modified Miles Assay {#S29}

Mice were injected with Evans blue dye (80mg/kg) via a carotid catheter at the beginning of reperfusion after 60 minutes of ischemia. After 2 hours of reperfusion, mice were euthanized and perfused with citrate buffer, pH4. The hearts were then excised, cut into 1mm thick slices and photographed. Heart slices were then incubated in 1ml of formamide overnight at 70 °C. After centrifugation, absorbance at 620 nm was measured by using a spectrophotometer Biotek \[Synergy 2 Multimode Microplate Reader (Winooski, VT)\]. Extravasated Evans blue (ng) was determined from a standard curve and normalized to tissue weight (g). Evans blue dye content was determined from standard curve and normalized to heart tissue weight ([@R19]).

### Chromatin immunoprecipitation (ChIP) assay from mouse heart tissue {#S30}

ChIP assays for heart tissue were performed using the SimpleChIP® Plus Enzymatic Chromatin IP Kit (Cell signaling). Briefly, freshly whole hearts were placed into PBS containing 1.5% formaldehyde and homogenized using a probe tissue homogenizer. Crosslinking was stopped after 15 min by adding glycine for 5min. The samples were centrifuged to collect the pellet. Pellets were disaggregated with a dounce homogenizer and chromatin was enzymatically digested to yield 200-to 1,500-bp DNA fragments. The chromatin was incubated at 4°C overnight with a HIF1A antibody (NB100-134, Novus, Littleton CO) or rabbit IgG control (Cell Signaling, Danvers, MA). After reverse cross-linking by heating the samples at 65°C overnight and treating with Proteinase K, DNA was purified using DNA purification kit (Cell Signaling, Danvers, MA). Quantitative analyses of DNA products obtained from ChIP assay were performed by real-time RT-PCR with primers specific for the mouse ANGPTL4 promoter. The ChIP data were normalized against IgG to account for non-specific immunoprecipitation (fold enrichment relative to the negative (IgG) sample). Primers used were: Primer 1: sense CCC CAC TTG CCA TCT GAA CT, antisense GAT GCC TTC TTG ACT GAC CCC, Primer 2: sense GGG AAT TTC CGG CCT TAG GAT, antisense GTT CTT GGG GAT GGC TGC TTC, Primer 3: sense CCT GGG ACG AGA TGA ACT TGC, antisense ATC TTT TCC CTT GGG CCC CT for the mouse ANGPTL4 promoter (see also [Figure S3](#SD1){ref-type="supplementary-material"}).

#### Hypoxia exposure {#S31}

For hypoxia experiments cells were placed in a hypoxia chamber (Coy Laboratory Products Inc., Grass Lake, MI) in preequilibrated hypoxic medium at 1% O~2~ for 24 hours.

### Lentiviral-mediated generation of cells with knockdown of PER2 or HIF1A {#S32}

Stable cell cultures with decreased PER2 and HIF1A expression were generated by lentiviral-mediated shRNA expression. pLKO.1 lentiviral vector targeting PER2 had shRNA sequence of CCG GGA CAC ACA CAA AGA ACT GAT ACT CGA GTA TCA GTT CTT TGT GTG TGT CTT TTT (TRCN0000018542) and HIF1A had shRNA sequence of CCG GCC AGT TAT GAT TGT GAA GTT ACT CGA GTA ACT TCA CAA TCA TAA CTG GTT TTT (TRCN 0000003809). For controls, nontargeting control shRNA (SHC002; Sigma) was used. HMEC-1 were co-transfected with pLK0.1 vectors and packaging plasmids to produce lentivirus. Filtered supernatants were used for infection of HMEC-1 and cells were selected with puromycin or geneticin until a knockdown was confirmed ([@R16]).

### Transcriptional Analysis {#S33}

Total RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA), phenol-chloroform extraction, and ethanol precipitation followed by purification in a modified protocol from RNeasy Mini Kit (QIAGEN, Germantown, MD). RNA was quantified using either a Qubit 3.0 RNA BR Assay Kit (Thermo Fisher Scientific, Waltham, MA) or Nanodrop 2000. Quantification of transcript levels was determined by real-time RT-PCR (iCycler; Bio-Rad Laboratories, Inc, Hercules, CA). qPCR reactions contained 1x final primer concentration (QIAGEN primers, Germantown, MD) or 1 μM sense and 1 μM antisense oligonucleotides (Invitrogen custom DNAoligos, Carlsbad, CA) with SYBR Green (Bio-Rad, Hercules, CA). Primer sets used (QIAGEN QuantiTect) were Hs_PER2_1\_SG (QT0011207), Hs_PKM_1\_SG (QT00028875), Hs_LDHA_1\_SG (QT00001687), Hs_SIRT3_1\_SG (QT00091490), Hs_ACTB_2\_SG (QT01680476), and Hs_COX4\|2_1\_SG (QT00044933), Mm_Per2_1\_SG (QT00198366), Mm_Angptl4_1\_SG (QT00139748), Mm_Cox4i2_1\_SG (QT00137844), Mm_Cldn1_1\_SG (QT00159278), Mm_Actb_2\_SG (QT01136772). Primers for human OPN4 (Invitrogen, Carlsbad, CA, sense 5′-AGT CGC CCC TAC CCC AGC TA-3′ and antisense 5′-CAC AGC TGC TGC CTC CAT GT-3′) were custom designed. Each target sequence was amplified using the following protocol: 95°C for 3 min, 40 cycles of 95°C for 15 s, 55°C for 0.5 min, 72°C for 10 s, 72°C for 1 min and a melt curve protocol.

### Immunoblotting experiments {#S34}

Protein was isolated from HMEC-1 using M-Per following manufacturer's instructions (Thermo Fisher Scientific, Waltham, MA) and including a protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA). Protein was quantified using a Qubit Fluorometer 3.0 and Qubit Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA). 5 -- 25 μg of protein was denatured at 95°C in Laemmli sample buffer for 5 min. Samples were resolved on a 4 - 10% polyacrylamide gel and transferred to nitrocellulose membranes, which were blocked for 1h at room temperature in either 5% BSA / TBST or 5% milk / TBST. The membranes were incubated in primary antibody at a concentration of 1:1000 overnight at 4°C. The primary antibodies used were rabbit polyclonal PER2 (Novus Biologicals, NB100-125, Littleton CO, or Abcam, ab64460, Cambridge, MA), mouse monoclonal actin (Ab-1) (JLA20, Calbiochem, Diego, CA,), rabbit polyclonal IDH2 (Novus Biologicals, NBP2-22166, Littleton CO), rabbit polyclonal SUCLG1 (Novus Biologicals, NBP1089489, Littleton CO), rabbit polyclonal ACO2 (Novus Biologicals, H00000050-D01P, Littleton CO), rabbit polyclonal SIRT3 (Abcam, ab86671, Cambridge, MA), anti-alpha Tubulin antibody (Abcam, ab7291, Cambridge, MA), Anti-VDAC1 / Porin antibody (Abcam, ab15895, Cambridge, MA), Anti-TATA binding protein (TBP) antibody (Abcam, ab51841, Cambridge, MA), mouse monoclonal β-ACTIN (Cell Signaling Technologies, 8H10D10, Danvers, MA), and mouse monoclonal anti-DDK (FLAG) (OriGene Technologies, TA50011-100, Rockville, MD). The next day, blots were washed 3 -- 4x with TBST and incubated with secondary antibody at a concentration of 1:5000 in the respective blocking buffer, washed an additional 3 times, and visualized using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, Waltham, MA). The secondary antibodies used were goat polyclonal IgG (Novus Biologicals, NB7487), goat anti-mouse IgM (Calbiochem, San Diego, CA), and goat anti-rabbit IgG (Thermo Fisher Scientific, Waltham, MA).

### Lactate measurements {#S35}

Lactate measurements were done using the L-Lactate Colorimetric Assay Kit following the manufacturer's protocol (Abcam, Cambridge, MA).

### Cytotoxicity {#S36}

Cytotoxicity was determined using the LDH-Cytotoxicity Assay Kit per manufacturer's protocol (Abcam, Cambridge, MA).

### Seahorse stress tests {#S37}

#### Glycolytic stress tests {#S38}

The XF24 Seahorse Bioanalyzer was used in conjunction with glycolytic stress tests following manufacturer's specifications (Agilent, Santa Clara, CA). Cells were plated in the morning at a density of 1.2×10^5^ cells/well and serum starved in the evening one day prior to assaying. One hour prior to the stress test cells were incubated in XF Assay Medium (Agilent, Santa Clara, CA) at a pH of 7.4. Final concentration of glucose was 10 mM / well, oligomycin 1.0 μM / well, and 2-deoxyglucose 50 mM / well.

#### Mitochondrial stress tests {#S39}

The XF24 Seahorse Bioanalyzer was used for mitochondrial stress tests (Agilent, Santa Clara, CA). For all assays, pH and oxygen consumption rate (OCR) were measured. For TCA cycle readouts, an additional measurement of carbon dioxide evolution rate (CDER) was measured. Final concentrations were 1.0 μM oligomycin, 3.6 μM FCCP, and 1.125 μM Rotenone / Antimycin A.

#### Cell energy phenotype assays {#S40}

Following manufacturer's instructions (Agilent, Santa Clara, CA), the Seahorse Bioanalyzer was used to assess cell energy phenotype at baseline.

### Chromatin immunoprecipitation (ChIP) assay- cell culture {#S41}

ChIP assays were performed using the ChIP-IT Express Enzymatic Kit from Active Motif (Carlsbad, CA, USA). Briefly, Scr and PER2KD HMECs were grown to 90% confluence in phenol red-free Dulbecco's modified Eagle medium (DMEM) supplemented with 10% charcoal DEXTRAN-stripped FBS for at least 3 days. After hypoxia exposure at 1% O~2~ for 24h, ChIP assays were performed according to manufacturer's protocol. Briefly, chromatin was cross-linked in 1% formaldehyde in minimal cell culture medium (Invitrogen, Carlsbad, CA), and nuclei were extracted. Chromatin was enzymatically digested for 11mins to yield 200- to 1,500-bp DNA fragments and the supernatant containing precleared chromatin was then incubated at 4°C overnight with mouse monoclonal HIF1A antibody (H1alpha67, ChIP Grade, Abcam, Cambridge, MA) or rabbit IgG control (Cell Signaling, Danvers, MA). After reverse crosslinking by heating the samples at 65°C overnight and treating with Proteinase K, DNA was purified using phenol-chloroform extraction. Quantitative analyses of DNA products obtained from ChIP assay were performed by RT-PCR with primers specific for the human LDHA promoter. RT-PCRs conducted on DNA derived from input chromatin templates served as positive controls whereas reactions conducted on IgG-precipitated templates served as negative controls. The RT-PCR signal was barely detectable for these controls. The signal for these samples and IgG-precipitated templates was negligible on gels. Primers used were: sense ATT ACG TGC CAG AAG CTG TT and antisense TTT CCT CAT CCA TGA AAC CT for the human LDHa promoter. Conventional PCR signals were stained with ethidium bromide in 1% agarose gels.

### Affinity purification-mass spectrometry-based proteomics {#S42}

HMEC-1 were placed in a hypoxia chamber (Coy Laboratory Products Inc., Grass Lake, MI) in preequilibrated hypoxic medium at 1% O~2~. Following 24 h of hypoxia, the samples were isolated for cytoplasmic and nuclear protein fractions according to the NE-PER kit specifications (Thermo Fisher Scientific, Waltham, MA). To identify interacting proteins with PER2, co-immunoprecipitation (Co-IP) for PER2 was performed using the Pierce Co-IP Kit (Thermo Fisher Scientific, Waltham, MA). Specifically, 10 μg of rabbit anti-PER2 antibody (Novus, NB100-125) was immobilized to the amine-reactive resin. 100 μg of sample was incubated overnight at 4°C with the anti-PER2 coupled resin. Samples were washed and then eluted. Samples were then loaded onto a 1.5 mm thick NuPAGE Bis-Tris 4%--12% gradient gel (Invitrogen, Carlsbad, CA). The BenchMark Protein Ladder (Invitrogen, Carlsbad, CA) was used as a protein molecular mass marker. The electrophoretic run was performing by using MES SDS running buffer, in an X-Cell II mini gel system (Invitrogen) at 200 V, 120 mA, 25 W per gel for 30 minutes. The gel was stained using SimplyBlue SafeStain (Invitrogen, Carlsbad, CA) stain and de-stained with water according to the manufacturer's protocol. Each lane of the gel was divided into 9 equal-sized bands, and proteins in the gel were digested as follows. Gel pieces were destained in 200 μL of 25 mM ammonium bicarbonate in 50% v/v acetonitrile for 15 min and washed with 200 μL of 50% (v/v) acetonitrile. Disulfide bonds in proteins were reduced by incubation in 10mM dithiothreitol (DTT) at 60°C for 30 min and cysteine residues were alkylated with 20 mM iodoacetamide (IAA) in the dark at room temperature for 45 min. Gel pieces were subsequently washed with 100 μL of distilled water followed by addition of 100 mL of acetonitrile and dried on SpeedVac (Savant, Thermo Fisher Scientific, Waltham, MA). Then 100 ng of trypsin was added to each sample and allowed to rehydrate the gel plugs at 4°C for 45 min and then incubated at 37°C overnight. The tryptic mixtures were acidified with formic acid up to a final concentration of 1%. Peptides were extracted two times from the gel plugs using 1% formic acid in 50% acetonitrile. The collected extractions were pooled with the initial digestion supernatant and dried on SpeedVac (Savant, Thermo Fisher Scientific, Waltham, MA). Samples were desalted on Thermo Scientific Pierce C18 Tip. For mass spectrometry, samples were analyzed on an LTQ Orbitrap Velos Pro mass spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled to an Eksigent nanoLC-2D system through a nanoelectrospray LC - MS interface. A volume of 8 μL of sample was injected into a 10 μL loop using the autosampler. To desalt the sample, material was flushed out of the loop and loaded onto a trapping column (ZORBAX 300SB-C18, dimensions 5×0.3 mm 5 μm) and washed with 0.1% FA at a flow rate of 5 μL/min for 5 min. The analytical column was then switched on-line at 600 nl/min over an in house-made 100 μm i.d. × 150mm fused silica capillary packed with 4 μm 80 Å Synergi Hydro C18 resin (Phenomex; Torrance, CA). After 10 min of sample loading, the flow rate was adjusted to 350 nL/min, and each sample was run on a 90-min linear gradient of 2%--40% ACN with 0.1% formic acid to separate the peptides. LC mobile phase solvents and sample dilutions used 0.1% formic acid in water (Buffer A) and 0.1% formic acid in acetonitrile (Buffer B) (Optima LC/MS, Fisher Scientific, Pittsburgh, PA). Data acquisition was performed using the instrument supplied Xcalibur (version 2.1) software. The mass spectrometer was operated in the positive ion mode. Data acquisition was performed using the instrument supplied Xcalibur (version 2.1) software. The mass spectrometer was operated in the positive ion mode. Full MS scans were acquired in the Orbitrap mass analyzer over the *m/z* 350--1800 range with resolution 60,000 *(m/z* 400). The target value was 5.00E+05. The twenty most intense were selected for sequencing and fragmented in the ion trap with normalized collision energy of 35%, activation q = 0.25, activation time of 20 ms, and one microscan. The target value was 1.00E+04. The maximum allowed ion accumulation times were 500 ms for full scans and 150 ms for CID. For database searching and protein identification, MS/MS spectra were extracted from raw data files and converted into mgf files using MassMatrix (Cleveland, OH). These mgf files were then independently searched against mouse SwissProt database using an in-house Mascot server (Version 2.2, Matrix Science). Mass tolerances were ± 15 ppm for MS peaks, and ± 0.6 Da for MS/MS fragment ions. Trypsin specificity was used allowing for 1 missed cleavage. Met oxidation, protein N-terminal acetylation, peptide N-terminal pyroglutamic acid formation were allowed for variable modifications while carbamidomethyl of Cys was set as a fixed modification. Scaffold (version 4.4.6, Proteome Software, Portland, OR, USA) was used to validate MS/MS based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than 95.0% probability as specified by the Peptide Prophet algorithm. Protein identifications were accepted if they could be established at greater than 99.0% probability and contained at least two identified unique peptides. Following identification of potential PER2 interacting proteins in normoxia, hypoxia, and normoxia versus hypoxia, lists obtained from Scaffold were analyzed by Ingenuity Pathway Analysis (QIAGEN), Panther Classification System, and Reactome Analysis to detect pathways PER2 regulates in normoxia and hypoxia.

### Co-immunoprecipitations (Co-IPs) {#S43}

Co-IPs were done using the Pierce Co-Immunoprecipitation (Co-IP) Kit (Thermo Fisher Scientific, Waltham, MA). 10 μg of antibody was immobilized to columns. Pulled-down protein was quantified using a Qubit Fluorometer 3.0 and resolved by immunoblotting as described.

### Subcellular compartment analysis {#S44}

HMEC-1 were placed in hypoxia (1% O~2~) or normoxia for 24 h. After normoxia or hypoxia exposure, samples were isolated for cytoplasmic and nuclear protein fractions according to the NE-PER kit specifications (Thermo Fisher Scientific, Waltham, MA). Mitochondria protein fraction was isolated with the Dounce homogenization method according to the Mitochondria Isolation Kit for Cultured Cells specifications (Thermo Fisher Scientific, Waltham, MA).

### Immunocytochemistry and analysis of PER2 localization to mitochondria {#S45}

Scr and PER2KD HMEC-1 cells were plated onto collagen coated coverslips and allowed to reach confluency. Following 24hrs of normoxia or hypoxia mitochondria were labeled using MitoTracker-deep red (100nM; Invitrogen) diluted in serum free media for 30mins at 37°C. Cells were then fixed with 4% PFA for 15mins at 37°C. Following PBS washes, samples were incubated with rabbit anti-Per2 (1:5000; Millipore) with 2% lamb serum and 0.1% Triton-X overnight at 4°C. Cells were then washed with PBS and incubated with Alexa Fluor goat-anti rabbit IgG-488 (1:500; Invitrogen) and DAPI (1:2000; Invitrogen). Following PBS washes, the cover-slips were mounted for imaging. Confocal immunofluorescent images were captured using a Zeiss 780 LSM confocal microscope with gain and laser power remaining constant between all samples. Samples were randomized and three images were blindly taken from each sample (n = 6/condition). Zen imaging software was used to assess Per2 fluorescent intensity and normalized to the total number of cells per 40x field. Colocalization of Per2 to mitochondria was assessed using ImageJ colocalization threshold analysis with Pearson's correlation coefficient being reported. Analysis of the three images from each sample was averaged for each sample. Representative images were chosen for figures to best depict the results obtained.

### Enzyme activities IDH, ACO, SUCLG, Complex IV, PFK {#S46}

Human isocitrate dehydrogenase (IDH, Biovision, Milpitas, CA), aconitase (ACO, Abcam, Cambridge, MA), succinyl-CoA synthetase (SUCLG, Abcam, Cambridge, MA), phosphofructokinase (PFK, Biovision, Milpitas, CA) or mouse complex 4 activity (Abcam, Cambridge, MA) were measure colorimetric assay kits adhering to manufacturer's instructions.

### Mitochondrial membrane potential dyes {#S47}

MitoTracker Red CMXRos (Invitrogen Molecular Probes, Carlsbad, CA) and JC-1 Mitochondrial Membrane Potential Assay (Abcam, Cambridge, MA) were used per manufacturer's specifications using 5 μM of JC-1 for 30 minutes at 37C. JC-1 quantification was done by calculating mean intensity.

### ^13^*C-tracers* in vitro {#S48}

HMEC-1 s were serum starved in either MCDB131 (low glucose) or glucose-free DMEM for 24 h prior to assay. Respective mediums were supplemented with either 12 mM U-^13^C-glucose (Cambridge Isotope Laboratories, Tewksbury, MA) or 166.67 μM 1,2-^13^C~2~-palmitic acid (Cambridge Isotope Laboratories, Tewksbury, MA) in hypoxia or normoxia for 24 h. Frozen cell pellets were extracted at 2e^6^ cells/mL in ice cold lysis/ extraction buffer (methanol:acetonitrile:water 5:3:2). Samples were agitated at 4°C for 30 min followed by centrifugation at 10,000 g for 10 min at 4°C. Protein and lipid pellets were discarded, and supernatants were stored at −80°C prior to metabolomics analysis. Ten μL of extracts were injected into a UHPLC system (Vanquish, Thermo, San Jose, CA, USA) and run on a Kinetex C18 column (150 × 2.1 mm, 1.7 μm - Phenomenex, Torrance, CA, USA). Solvents were Optima H2O (Phase A) and Optima acetonitrile (Phase B) supplemented with 0.1% formic acid for positive mode runs and 1 mM NH4OAc for negative mode runs. For \[U-^13^C\]-glucose flux analysis ([@R65]), samples were run on a 3 min isocratic (95% A, 5% B) run at 250 μL/min ([@R45]; [@R46]). For \[1,2-^13^C~2~\]-palmitate flux analysis, samples were analyzed using a 9 min gradient from 5%--95% acetonitrile organic phase at 400 μL/min. The autosampler was held at 7°C for all runs; the column compartment was held at 25°C for the 3 min method and 45°C for the 9 min method ([@R41]). The UHPLC system was coupled online with a Q Exactive mass spectrometer (Thermo, Bremen, Germany), scanning in Full MS mode (2 μscans) at 70,000 resolution in the 60-900 m/z range in negative and then positive ion mode (separate runs). Eluate was subjected to electrospray ionization (ESI) with 4 kV spray voltage. Nitrogen gas settings were 15 sheath gas and 5 auxiliary gas for the 3 min runs; 45 sheath gas and 15 auxiliary gas for the 9 min runs. Metabolite assignments and isotopologue distributions were determined using Maven (Princeton, NJ, USA), upon conversion of '.*raw'* files to '.*mzXML*' format through MassMatrix (Cleveland, OH, USA). Chromatographic and MS technical stability were assessed by determining CVs for heavy and light isotopologues in a technical mixture of extract run every 10 injections.

### Cell permeability - TEER method {#S49}

HMEC-1 were grown on polycarbonate permeable supports (0.4-μm pore, 6.5-mm diam; Corning Life Sciences, Acton, MA) at a cell density of 0.3 × 10^4^ cells/well. Confluent HMEC-1 were placed in a hypoxia chamber (Coy Laboratory Products Inc., Grass Lake, MI) in preequilibrated hypoxic medium at 1% O~2~. Transendothelial electrical resistance (TEER) was measured with the EVOM2 voltohm-meter (World Precision Instrument, Sarasota, FL, USA). Value of blank well was subtracted.

### Light sensing cells {#S50}

HMEC-1 WT cells were transfected with pCMV6-Entry (C-terminal Myc and DDK Tagged, OriGene Technologies, Rockville, MD) or OPN4 (Myc-DDK-Tagged)-pCMV6-Entry transcript variant 1 (TrueORF Gold Expression-Validated cDNA Clones from OriGene Technologies, Rockville, MD) using FuGene HD Transfection Reagent (Promega, Madison, WI). After transfection, cells were kept in complete darkness until room light (\~200 LUX) or intense light (\~10,000 LUX) exposures for 30 minutes. Melanopsin protein expression validation was done by isolating protein using RIPA buffer (Thermo Fisher Scientific, Waltham, MA) supplemented with protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA). Immunoblotting for anti-DDK (OriGene Technologies, Rockville, MD) was used to detect DDK-tagged melanopsin in transfected cells. Light-sensing cells subjected to glycolytic or mitochondrial stress tests on the Seahorse Bioanalyzer were exposed to light 30 min prior to Seahorse analyses.

### cAMP ELISA and phospho-CREB assays {#S51}

Phospho-CREB (S133) Immunoassay (R&D Systems, Minneapolis, MN) or cAMP Parameter Assay Kit for human (R&D Systems, Minneapolis, MN) were used according to the manufacturer's protocol.

### Human light exposure {#S52}

Healthy human volunteers were exposed to intense light exposure (10,000 LUX) for 30 min every morning for five days from 8:30 AM - 9:00 AM. 5mL blood was drawn on day one at 8:30 AM and 9:00 AM (before and after light exposure). While light exposure was repeated every morning for the five days, the next blood draws were on day two, three and five at 9:00 AM as indicated. In subset of experiments blood draws were also performed at 9 PM after 5 days of intense light therapy. For experiments involving actigraphy watches, the same volunteers wore the watch for one week without intense light exposure and maintained wearing the watches during the second week when light exposure was included. Actigraphy data were obtained by using a validated accelerometer (Actiwatch 2). We obtained approval from the Institutional Review Board (COMIRB \#13-1607) for our human studies prior to written informed consent from everyone. A total of 17 healthy volunteers were enrolled (11 female and 6 male, age range between 21-44 years.).

### Human plasma melatonin, HIF1A and triglyceride levels {#S53}

Melatonin levels were measured using the MT Elisa Kit for humans (My BioSource, San Diego, CA). HIF1A levels from human plasma samples were measured using the human HIF1A ELISA Kit from Invitrogen (Carlsbad, CA). Triglycerides were determined using a human Triglyceride Quantification Assay kit (Abcam, Cambridge, MA).

### Targeted metabolomics - mass spectrometry {#S54}

Targeted metabolomics of human plasma following light exposure was performed as previously reported (A three-minute method for high-throughput quantitative metabolomics and quantitative tracing experiments of central carbon and nitrogen pathways ([@R46]). In brief, plasma samples were diluted at 1:25 in ice cold extraction solution (methanol, acetonitrile, water at a ratio of 5:3:2) and vortexed for 30 minutes at 4°C followed by removal of insoluble proteins and lipids by centrifugation at 10,000 RCF for 10 minutes at 4°C. The supernatants were collected and stored at −80°C until analysis. Analyses were performed using a Vanquish UHPLC system coupled to a Q Exactive mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA). Samples were resolved by a Kinetex C18 column (2.1 × 150 mm, 1.7 μm particle size; Phenomenex, Torrance, CA, USA) with a guard column at 25°C with an isocratic condition of 5% acetonitrile, 95% water, and 0.1% formic acid with a flow rate of 250 μL/min. The mass spectrometer was operated independently in positive or negative ion mode, scanning in Full MS mode from 60 to 900 m/z at 70,000 resolutions, with 4 kV spray voltage, 15 sheath gas, 5 auxiliary gas. Calibration was performed prior to analysis. Acquired data was converted from. raw to. mzXML file format using Mass Matrix (Cleveland, OH, USA). Metabolite assignments, isotopologue distributions, and correction for expected natural abundances of deuterium, 13C, and 15N isotopes were performed using MAVEN (Princeton, NJ, USA). Metabolite assignments were referenced to experimental retention times for over 400 analytical standards (MSMLS, IROATech, Bolton, MA, USA) and were determined over a 3-minute isocratic method with 20 μL of standards and samples injected for UHPLC/MS analysis.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S55}
---------------------------------------

For comparison of two groups the unpaired Student's t test was performed. For multiple group comparisons a one-way analysis of variance with a Tukey's post hoc test was performed. Values are expressed as mean ± SD. Assay details and n numbers are specified in the figure legends. p \< 0.05 was considered statistically significant. Only two-sided tests were used, and all data analyzed met the assumption for the specific statistical test that was performed. For all statistical analysis, GraphPad Prism 7.0 software was used. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.

DATA AND CODE AVAILABILITY {#S56}
--------------------------

The Array data have been deposited in the Array Express database at EMBL-EBI (<https://www.ebi.ac.uk/arrayexpress/>) under accession number E-MTAB-7196 (<http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7196>).
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![Intense Light-Elicited Circadian PER2 Amplitude Enhancement in Cardio-protection\
(A--C) C57BL/6 mice housed under intense light (IL; 10,000 lux, L:D 14:10 h) for 3,5, or 7 days were subjected to 60 min of *in situ* myocardial ischemia followed by 2 h reperfusion at ZT3 (9 a.m.) and compared with mice housed under standard room light (RL; 200 lux, L:D 14:10h,7 days) (mean ± SD; n = 6; ANOVA with Tukey's multiple comparison test).\
(A) Infarct size measurements.\
(B) Parallel measurements of serum troponin-I by ELISA (mean ± SD; n = 6; ANOVA with Tukey's multiple comparison test).\
(C) Representative images of infarcts.\
(D--F) Wheel running measurements during 7 days of RL or IL housing in C57BL/6J mice (L, light phase; D, dark phase; n = 6; Student's t test).\
(D) Wheel running activity graphs.\
(E) Distance walked.\
(F) Circadian amplitude.\
(G) Cardiac PER2 luciferase activity indicating protein in mice after RL or IL for 7 days (mean ± SD; n = 4; all IL versus RL p \< 0.05 via ANOVA with Tukey's multiple comparison test).\
(H--J) Wheel running during 7 days of RL or IL housing in C57BL/6J and *Per2*^−/−^ mice (n = 5--6; ANOVA with Tukey's multiple comparison test).\
(H) Distance walked.\
(I) Circadian amplitude.\
(J) Wheel running activity graphs.\
(K and L) Immunoblot and quantification for PER2 protein in seeing or enucleated (blind) C57BL/6J mice after 7 days of RL or IL at ZT3 (mean ± SD; n = 5; Student's t test).\
(K) Immunoblot.\
(L) Protein quantification.\
(M) Troponin-I serum levels in seeing or blind C57BL/6J mice housed under RL conditions followed by 60 min ischemia and 2 h reperfusion at ZT3 or ZT15 (mean ± SD; n = 4; ANOVA with Tukey's multiple comparison test).\
(N) Wheel running measurements during 7 days of RL or IL housing in blind C57BL/6J mice (mean ± SD; n = 4; Student's t test).\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1536798-f0001){#F1}

![Intense Light Increases Cardiac Adenosine-cAMP and Glycolytic Flux via PER2 in the Uninjured Heart\
(A) Infarct sizes in C57BL/6J mice that were housed under intense light (IL; 10,000 lux, L:D 14:10 h) for 7 days and subjected to 60 min of *in situ* myocardial ischemia followed by 2 h reperfusion at ZT3 or ZT15 (mean ± SD; n = 6; Student's t test).\
(B--D) C57BL/6J mice exposed to voluntary wheel running for 1 versus 2 weeks. Shown are infarct sizes after 60 min of myocardial ischemia and 2 h reperfusion at ZT3 (B) or circadian amplitude (C) and distance walked measurements in relation to infarct sizes (D, mean ± SD; n = 6; Student's t test).\
(E--H) Wheel running measurements during or infarct size studies after 2 weeks of wheel running at ZT3 in C57BL/6J or *Per2*^−/−^ mice (mean ± SD; n = 5; Student's t test).\
(E) Distance walked.\
(F) Circadian amplitude.\
(G and H) Infarct size measurements (G) and one representative infarct size staining and one wheel running activity recording are shown (H).\
(I and J) Adenosine (I) or cAMP (J) levels in heart tissue from C57BL/6J or *Per2*^−/−^ mice at ZT3 after 7 days of room light (RL; 200 lux, L:D 14:10 h) or intense light (IL; 10,000 lux, L:D 14:10 h) housing (mean ± SD; n = 5; ANOVA with Tukey's multiple comparison test).\
(K) Cardiac U-^13^C-glucose-1,6-bisphosphate levels at ZT3 from C57BL/6J mice that were housed under RL or IL for 7 days (mean ± SD; n = 4; Student's t test).\
(L and M) Phosphofructokinase (PFK) activity in both heart tissue (L) and plasma samples (M) from C57BL/6J or *Per2*^−/−^ mice at ZT3 after 7 days of RL or IL housing (mean ± SD; n = 4--5; ANOVA with Tukey's multiple comparison test).\
(N) HIF1A-hypoxia response element (HRE) binding was determined at ZT3, ZT9, ZT15, and ZT21 (mean ± SD; n = 5; \*p \< 0.05 for ZT21 versus ZT3 in RL- and IL-housed mice via Student's t test).\
(O) C57BL/6J or *Per2*^−/−^ mice housed under IL for 7 days before 60 min myocardial ischemia and 2 h reperfusion at ZT3 (mean ± SD; n = 5; Student's t test).\
(P) Representative infarct staining.](nihms-1536798-f0002){#F2}

![Intense Light-Elicited Cardioprotection Is Endothelial PER2 Specific\
(A) Whole-genome array from C57BL/6J or *Per2*^−/−^ heart tissue after 7 days of intense light (IL; 10,000 lux, L:D 14:10 h) or standard room light (RL; 200 lux, L:D 14:10 h) housing at ZT3 (n = 3 per group, total of 12 arrays). Top light-regulated pathways are shown.\
(B) Validation of transcript levels of the top light and PER2-dependent gene (ANGPTL-4) identified by whole-genome array (mean ± SD; n = 4--5; Student's t test).\
(C) *Per2* mRNA transcript levels from endothelial cells isolated from endothelial-specific PER2-deficient (*Per2*^*loxP/loxP*^-VE-Cadherin-Cre) or control (VE-Cadherin-Cre) hearts (mean ± SD; n = 3; Student's t test).\
(D and E) Infarct sizes (D) or serum troponin-I (E) in *Per2^loxP/loxP^*-VE-Cadherin-Cre) or VE-Cadherin-Cre mice housed under RL or IL conditions for 7 days followed by 60 min of *in situ* myocardial ischemia and 2 h reperfusion at ZT3 (mean ± SD; n = 5; ANOVA with Tukey's multiple comparison test).\
(F) Representative infarct staining.\
(G--I) Vascular leakage of Evans blue dye in C57BL/6J (G and H) or *Per2^loxP/loxP^*-VE-Cadherin-Cre (I) after 60 min of *in situ* myocardial ischemia and 2 h reperfusion at ZT3 following 7 days of RL or IL housing (mean ± SD; n = 5; Student's t test for G and ANOVA with Tukey's multiple comparison test for I).\
(G) Vascular leakage quantification in C57BL/6J.\
(H) Representative Evans blue staining in C57BL/6J.\
(I) Per2loxP/loxP-VE-Cadherin-Cre.\
(J) Vascular leakage of Evans blue dye in *Ador-a2b*^−/−^ after 60 min of *in situ* myocardial ischemia and 2 h reperfusion at ZT3 following 7 days of RL or IL housing (mean ± SD; n = 5; Student's t test).\
(K) ChIP assay for HIF1A binding to the promoter region of Angptl4 in C57BL/6J following 7 days of RL or IL housing (mean ± SD; n = 3; Student's t test).\
See also [Figures S2](#SD1){ref-type="supplementary-material"} and [S3](#SD1){ref-type="supplementary-material"}.](nihms-1536798-f0003){#F3}

![Identification of Endothelial PER2 as a Regulator of TCA Cycle Activity\
HMEC-1 or stable lentiviral-mediated PER2KD and Scr control HMEC-1 were synchronized and exposed to 24 h of normoxia (Nx) or 1% hypoxia (Hx). In a subset of experiments, synchronized stable lentiviral-mediated HIF1AKD and Scr HMEC-1 were exposed to Nx or Hx.\
(A and B) Affinity purification-mass spectrometry-based proteomics screen for PER2 protein interactions in normoxic and hypoxic HMEC-1.\
(A) Number of PER2 proteins regulated.\
(B) Pathways analysis using Ingenuity.\
(C and D) Coimmunoprecipitation for PER2 in hypoxic or normoxic HMEC-1 against isocitrate dehydrogenase (IDH) 2, succinyl coenzyme A (CoA) ligase (SUCLG) 1, and aconitase (ACO) 2 (C), and vice versa (D). One representative blot of three is displayed.\
(E) Subcellular compartment analysis of PER2 during normoxia or hypoxia (C, cytoplasm; N, nucleus; M, mitochondria; compartment-specific loading controls: tubulin alpha 1a (TUBA1A) for cytoplasm, TATA-box binding protein (TBP) for nucleus, and voltage-dependent anion channel 1 (VDAC1) for mitochondria).\
(F) Translocation of PER2 into the mitochondria during hypoxia (scale bar, 20 μm).\
(G--I) TCA cycle enzyme activities of IDH (G), SUCLG (H), and ACO (I) from stable lentiviral-mediated PER2KD and Scr control HMEC-1 during hypoxia (mean ± SD; n = 3; Student's t test).\
(J) Carbon dioxide evolution rate (CDER), as a surrogate for TCA cycle function, in PER2KD or Scr HMEC-1 measured by a mitochondrial stress test using a Seahorse XF24 FluxPak assay (mean ± SD; n = 5; Student's t test).\
(K--M) SIRT3 transcript (K and L) or protein (M) levels from stable lentiviral-mediated PER2KD and Scr (K and M, upper panel) or stable lentiviral-mediated HIF1AKD and Scr (L and M, lower panel) control HMEC-1 (mean ± SD; n = 3; ANOVA with Tukey's multiple comparison test).\
See also [Figures S4](#SD1){ref-type="supplementary-material"}--[S7](#SD1){ref-type="supplementary-material"}.](nihms-1536798-f0004){#F4}

![Endothelial PER2 Regulates Mitochondrial ATP Production and Barrier Function\
(A--D) Oxygen consumption rates (OCRs) in PER2KD or Scr HMEC-1. Quantification of basal respiration, maximum achievable respiration, and ATP production are shown (mean ± SD; n = 5; Student's t test).\
(A) Seahorse mitochondrial stress test.\
(B) Basal respiration.\
(C) Maximal respiration.\
(D) ATP production.\
(E) COX4.2 transcript levels in PER2KD or Scr HMEC-1 after 24 h of Nx or 1% Hx treatment (mean ± SD; n = 6; ANOVA with Tukey's multiple comparison test).\
(F) Complex IV enzyme activity in *Per2*^−/−^ or C57BL/6 mouse hearts subjected to 45 min of ischemia (mean ± SD; n = 4; ANOVA with Tukey's multiple comparison test).\
(G) Cardiac *Cox42* mRNA levels at ZT3, ZT9, ZT15, and ZT21 in C57BL/6 mice after 7 days of room light (RL) or intense light (IL) housing (mean ± SD; n = 5; \#p \< 0.05 for ZT3 IL versus ZT3 in RL-housed mice via two-way ANOVA with Sidak's multiple comparison test).\
(H) MitoTracker red CMXRos staining of PER2KD or Scr HMEC-1 at baseline. One representative image of five is shown (scale bar, 20 μm).\
(I) Quantification of the mitochondrial membrane potential probe JC-1 (mean ± SD; n = 6; ANOVA with Tukey's multiple comparison test).\
(J--M) ^13^C metabolites from supernatants of PER2KD or Scr HMEC-1 following 24 h of Nx or 1 % Hx treatment. Data are presented as the percentage of total metabolites present (mean ± SD; n = 3; ANOVA with Tukey's multiple comparison test).\
(J) ^13^C fructose-6-phosphate.\
(K) ^13^C α-ketoglutarate.\
(L) ^13^C 6-phosphogluconate.\
(M) ^13^C palmitic acid.\
(N) Permeability assay in PER2KD or Scr HMEC-1 during 24 h of 1% hypoxia (mean ± SD; n = 5; two-way ANOVA with Tukey's multiple comparison test). Note that permeability increases after prolonged hypoxia exposure of endothelial cells due to morphological changes.\
(O) *CLDN1* (claudin-1) transcript levels in PER2KD or Scr HMEC-1 after 4 h of Nx or 1% Hx treatment (mean ± SD; n = 3; ANOVA with Tukey's multiple comparison test).\
(P) Cardiac *Cldn1* mRNA was determined at ZT3, ZT9, ZT15, and ZT21 in C57BL/6 mice after 7 days of RL or IL treatment (mean ± SD; n = 5; \#p \< 0.05 for ZT3 IL versus ZT3 in RL-housed mice via two-way ANOVA with Sidak's multiple comparison test).\
See also [Figures S8](#SD1){ref-type="supplementary-material"} and [S9](#SD1){ref-type="supplementary-material"}.](nihms-1536798-f0005){#F5}

![Light-Sensing Human Cell Line Recapitulates *In Vivo* Light Exposure\
(A) Study design and verification of melanopsin overexpression by immunoblot. pCMV6 is the empty vector control, and OPN4-pCMV6 is the plasmid containing the gene encoding melanopsin (n = 3).\
(B--H) cAMP (B), pCREB levels (C), PER2 transcript (D) seahorse glycolytic stress test (E), glycolytic capacity (F), seahorse mitochondrial stress test (G), and maximum achievable respiration (H) after light-sensing cells were exposed to intense light (mean ± SD; n = 6--10; Student's t test).\
(I) Schematic model.](nihms-1536798-f0006){#F6}

![Intense Light Enhances the Circadian Amplitude of PER2 and Activates PER2 Metabolism in Humans\
(A) Protocol for intense light exposure experiments in healthy human volunteers. 20 healthy volunteers (11 female and 6 male, age range between 21 and 44 years) were exposed to intense light (10,000 lux) from 8:30--9:00 a.m. on 5 consecutive days.\
(B and C) PER2 protein levels from buccal tissue (B) or plasma samples (C) at 9 a.m. during 5 days of intense light exposure assessed by immunoblot or ELISA, respectively (mean ± SD; n = 6; ANOVA with Tukey's multiple comparison test).\
(D) Effect of room light versus intense light on human plasma melatonin levels (mean ± SD; n = 3--6; ANOVA with Tukey's multiple comparison test).\
(E) Longitudinal monitoring of human plasma melatonin levels during 5 days of intense light exposure at 9 a.m. (mean ± SD; n = 3--6; ANOVA with Tukey's multiple comparison test).\
(F) Human plasma phosphofructokinase (PFK) activity during 5 days of intense light exposure at 9 a.m. (mean ± SD; n = 3--6; ANOVA with Tukey's multiple comparison test).\
(G) Human plasma PFK activity after 5 days of intense light exposure at 9 p.m. (mean ± SD; n = 3; Student's t test).\
(H) Human plasma triglyceride levels during 5 days of intense light exposure at 9 a.m. (mean ± SD; n = 8; ANOVA with Tukey's multiple comparison test).\
(I--K) Targeted metabolomics using mass spectrometry on human plasma samples from healthy volunteers exposed to intense light therapy for 5 days. (I) Pathway analysis. Key metabolites of glycolysis (pyruvate) or the TCA cycle (succinate, K) are shown for day 3 and day 5 of intense light therapy (mean ± SD; n = 3; ANOVA with Tukey's multiple comparison test).\
(L--P) Actigraphy data using a validated accelerometer (Actiwatch 2). Shown are the wake after sleep onset (WASO) episodes (L), sleep efficiency (M), day activity (N), circadian amplitude (O) (mean ± SD; n = 6; Student's t test), and one representative actigraphy recording from one healthy volunteer (P) before and during intense light therapy (synchronized sleep phases \[turquoise bar\] during intense light exposure \[red square\]). C, control subjects before light exposure; IL, intense light.\
See also [Figures S10](#SD1){ref-type="supplementary-material"} and [S11](#SD1){ref-type="supplementary-material"}.](nihms-1536798-f0007){#F7}

###### 

KEY RESOURCE TABLE

  REAGENT or RESOURCE                                                                                 SOURCE                              IDENTIFIER
  --------------------------------------------------------------------------------------------------- ----------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  Antibodies                                                                                                                              
  Rabbit polyclonal anti-HIF1A antibody                                                               Novus                               Cat\# NB100-134, RRID:AB_350071
  Mouse monoclonal HIF1A antibody (H1alpha67)                                                         Abcam                               Ca\# ab1, RRID: AB_296474
  Rabbit polyclonal anti-PER2 antibody                                                                Novus                               Cat\# NB100-125, RRID:AB_10000765
  Rabbit anti-Per2 antibody                                                                           Millipore                           Ca\# AB2202, RRID:AB_1587380
  Rabbit polyclonal anti-IDH2 antibody                                                                Novus                               Cat\# NBP2-22166
  Rabbit polyclonal anti-SUCLG1 antibody                                                              Novus                               Cat\# NBP1-89489, RRID:AB_11055051
  Rabbit polyclonal anti-ACO2 antibody                                                                Novus                               Cat\# H00000050-D01P, RRID:AB_1672898
  Rabbit polyclonal anti-SIRT3 antibody                                                               Abcam                               Cat\# ab86671, RRID:AB_10861832
  Mouse anti-alpha Tubulin antibody                                                                   Abcam                               Cat\# ab7291, RRID:AB_2241126
  Rabbit anti-VDAC1 / Porin antibody                                                                  Abcam                               Cat\# ab15895, RRID:AB_2214787
  Mouse anti-TATA binding protein (TBP) antibody                                                      Abcam                               Cat\# ab51841, RRID:AB_945758
  Mouse monoclonal anti- β-ACTIN antibody                                                             Cell Signaling                      Cat\# 8H10D10, RRID:AB_11188565
  Anti-Actin (Ab-1) Mouse mAb (JLA20)                                                                 Calbiochem                          Ca\# CP01, RRID:AB_566293
  Mouse monoclonal anti-DDK (FLAG) antibody                                                           OriGene                             Cat\# TA50011-100, RRID:AB_2622345
  Goat anti-Human polyclonal IgG secondary antibody                                                   Novus                               Cat\# NB7487, RRID:AB_10124626
  Goat anti-mouse IgG secondary antibody                                                              Thermo Fisher Scientific            Ca\# 31430, RRID:AB_228307
  Goat anti-rabbit IgG secondary antibody                                                             Thermo Fisher Scientific            Ca\# 31460, RRID:AB_228341
  Alexa Fluor goat-anti rabbit IgG-488                                                                Invitrogen                          Cat\# A27034, RRID:AB_2536097
  Bacterial and Virus Strains                                                                                                             
  pCMV6-Entry (C-terminal Myc and DDK Tagged)                                                         OriGene Technologies                Cat\# PS100001
  OPN4 (Myc-DDK-Tagged)-pCMV6-Entry transcript variant 1                                              OriGene Technologies                Ca\# MR225286
  Chemicals, Peptides, and Recombinant Proteins                                                                                           
  Evans blue                                                                                          Sigma-Aldrich                       Cat\# E2129; Cas: 314-13-6
  2,3,5-Triphenyltetrazolium chloride (TTC)                                                           Sigma-Aldrich                       Cat\# T8877; Cas: 298-96-4
  T-PER Tissue Protein Extraction Reagent                                                             Thermo Fisher Scientific            Cat\# 78510
  NE-PER Nuclear and Cytoplasmic Extraction Reagents                                                  Thermo Fisher Scientific            Cat\# 78835
  M-PER Mammalian Protein Extraction Reagent                                                          Thermo Fisher Scientific            Cat\# 78501
  Mitochondria Isolation Kit for Cultured Cells                                                       Thermo Fisher Scientific            Cat\# 89874
  U-^13^C-glucose                                                                                     Cambridge Isotope Laboratories      Cat\# CLM-1396-PK
  Trizol Reagent                                                                                      Thermo Fisher Scientific            Cat\# 15596018
  SuperSignal West Femto Maximum Sensitivity Substrate                                                Thermo Fisher Scientific            Cat\# 34096
  MitoTracker Deep Red FM                                                                             Thermo Fisher Scientific            Cat\# M22426
  MitoTracker Red CMXRos                                                                              Thermo Fisher Scientific            Ca\# M7512
  JC-1 Mitochondrial Membrane Potential Assay Kit                                                     Abcam                               Ca\# 113850
  FuGene HD Transfection Reagent                                                                      Promega                             Ca\# E2311
  Critical Commercial Assays                                                                                                              
  Mouse Cardiac Troponin-I ELISA                                                                      Life Diagnostics, Inc               Cat\# CTNI-1-HS
  Dual-Luciferase Reporter Assay System                                                               Promega                             Cat\# E1910
  Phosphofructokinase (PFK) Activity Colorimetric Assay Kit                                           BioVision                           Cat\# K776
  Mouse/Rat cAMP Parameter Assay Kit                                                                  R&D systems                         Cat\# KGE012
  cAMP Parameter Assay Kit for human sample                                                           R&D systems                         Cat\# KGE002B
  HIF1A Transcription Factor Assay kit                                                                Abcam                               Cat\# ab133104
  BCA Protein Assay Kit                                                                               Thermo Fisher Scientific            Cat\# 23225
  RNeasy Mini Kit                                                                                     QIAGEN                              Cat\# 74106
  Mouse Clariom D arrays                                                                              Thermo Fisher Scientific            Cat\# 902514
  SimpleChIP Plus Enzymatic Chromatin IP Kit                                                          Cell signaling                      Cat\# 9005
  Qubit 3.0 RNA BR Assay Kit                                                                          Thermo Fisher Scientific            Cat\# Q10211
  Qubit Fluorometer 3.0 and Qubit Protein Assay Kit                                                   Thermo Fisher Scientific            Cat\# Q33211
  iQ SYBR Green Supermix                                                                              Bio-rad                             Cat\# 1708880
  L-Lactate Assay Kit                                                                                 Abcam                               Ca\# ab65331
  LDH-Cytotoxicity Assay Kit                                                                          Abcam                               Ca\# ab197004
  ChIP-IT Express Chromatin Immunoprecipitation Kits                                                  Active Motif                        Ca\# 53009
  Pierce Co-Immunoprecipitation (Co-IP) Kit                                                           Thermo Fisher Scientific            Ca\# 26149
  Phospho-CREB (S133) Immunoassay                                                                     R&D Systems                         Cat\# DYC2510-2
  Human MT (Melatonin) ELISA Kit                                                                      MyBioSource                         Cat\# MBS766108
  human HIF1A ELISA Kit                                                                               Invitrogen                          Cat\# EHIF1A
  Triglyceride Assay Kit - Quantification                                                             Abcam                               Cat\# ab65336
  Deposited Data                                                                                                                          
  Microarray data                                                                                     This paper                          EMBL-EBI (<https://www.ebi.ac.uk/arrayexpress/>) under accession number E-MTAB-7196 (<http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7196>).
  Experimental Models: Cell Lines                                                                                                         
  Human microvascular endothelial cells (HMEC-1)                                                      ATCC                                ATCC® CRL-3243
  Experimental Models: Organisms/Strains                                                                                                  
  Mouse: C57BL/6J                                                                                     Jackson laboratories                JAX: 000664
  Mouse: *Per2tm1Brd Tyrc-Brd/J (Per2*^−/−^*)*                                                        Jackson laboratories ([@R77])       JAX: 003819
  Mouse: B6.129S6-*Per2*^*tm1Jt*^/J (PER2 luciferase)                                                 Jackson laboratories ([@R71])       JAX: 006852
  Mouse: Per2^*loxp/loxp*^                                                                            generated by Ozgene                 N/A
  Mouse: Adorab2^*loxp/loxp*^                                                                         generated by Ozgene                 N/A
  Mouse: B6.Cg-Tg(Cdh5-cre)7Mlia/J (VE-Cadherin-Cre)                                                  Jackson laboratories ([@R3])        JAX: 006137
  Mouse: B6.C-Tg(CMV-cre)1Cgn/J (Germline Cre)                                                        Jackson laboratories                JAX: 006054
  Oligonucleotides                                                                                                                        
  Primer: mouse ANGPTL4 promoter 1 sense: CCC CAC TTG CCA TCT GAA CT                                  This paper                          N/A
  Primer: mouse ANGPTL4 promoter 1 antisense: GAT GCC TTC TTG ACT GAC CCC                             This paper                          N/A
  Primer: mouse ANGPTL4 promoter 2 sense: GGG AAT TTC CGG CCT TAG GAT                                 This paper                          N/A
  Primer: mouse ANGPTL4 promoter 2 antisense: GTT CTT GGG GAT GGC TGC TTC                             This paper                          N/A
  Primer: mouse ANGPTL4 promoter 3 sense: CCT GGG ACG AGA TGA ACT TGC                                 This paper                          N/A
  Primer: mouse ANGPTL4 promoter 3 antisense: ATC TTT TCC CTT GGG CCC CT                              This paper                          N/A
  PER2 shRNA sequence: CCG GGA CAC ACA CAA AGA ACT GAT ACT CGA GTA TCA GTT CTT TGT GTG TGT CTT TTT    This paper                          TRCN0000018542
  HIF1A shRNA sequence: CCG GCC AGT TAT GAT TGT GAA GTT ACT CGA GTA ACT TCA CAA TCA TAA CTG GTT TTT   This paper                          TRCN 0000003809
  Control shRNA                                                                                       Sigma-Aldrich                       Cat\# SHC002
  Hs_PER2_1\_SG                                                                                       QIAGEN                              Cat\# QT0011207
  Hs_ACTB_2\_SG                                                                                       QIAGEN                              Cat\# QT01680476
  Hs_COX4\|2_1\_SG                                                                                    QIAGEN                              Cat\# QT00044933
  Mm_Per2_1\_SG                                                                                       QIAGEN                              Cat\# QT00198366
  Mm_Angptl4_1\_SG                                                                                    QIAGEN                              Cat\# QT00139748
  Mm_Actb_2\_SG                                                                                       QIAGEN                              Cat\# QT01136772
  Mm_Cox4i2_1\_SG QuantiTect Primer Assay                                                             QIAGEN                              Cat\# QT00137844
  Mm_Cldn1_1\_SG QuantiTect Primer Assay                                                              QIAGEN                              Cat\# QT00159278
  Primer: human OPN4 sense: AGT CGC CCC TAC CCC AGC TA                                                This paper                          N/A
  Primer: human OPN4 antisense: CAC AGC TGC TGC CTC CAT GT                                            This paper                          N/A
  Primer: human LDHa promoter sense: ATT ACG TGC CAG AAG CTG TT                                       This paper                          N/A
  Primer: human LDHAa promoter antisense: TTT CCT CAT CCA TGA AAC CT                                  This paper                          N/A
  Software and Algorithms                                                                                                                 
  ImageJ                                                                                              National Institute of Health, USA   <https://imagej.nih.gov/ij/>
  Vital View Data Acquisition System                                                                  Starr Life Sciences                 N/A
  BioDare 2                                                                                           [@R44]                              <https://biodare2.ed.ac.uk/>
  Affymetrix GCOS 1.3 software                                                                        Affymetrix                          N/A
  MAS 5.0 algorithm                                                                                   Affymetrix                          N/A
  Transcriptome Analysis Console (TAC) software                                                       Affymetrix                          N/A
  Xcalibur (version 2.1) software                                                                     Thermo Scientific                   N/A
  Ingenuity Pathway Analysis                                                                          QIAGEN                              N/A
  GraphPad Prism 7.0 software                                                                         GraphPad software                   N/A
  Other                                                                                                                                   
  Lightbox: 10,000 LUX, Lightbox, full spectrum, UV filter                                            Uplift Technologies                 DL930
  Actiwatch 2                                                                                         Philips                             N/A

###### Highlights

-   Intense light-mediated cardioprotection requires endothelial-specific PER2

-   Intense light-elicited PER2 transcriptionally reprograms the endothelium

-   Endothelial PER2 regulates respiration and barrier function during hypoxia

-   Studies of humans reveal intense light activates PER2-dependent metabolism
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